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There are many confounding factors 
related to pain treatment in older 
people and concerns have been 
raised regarding the management of 
pain. This study aimed to determine 
the pattern of analgesic use, the 
persistence of chronic pain, and 
factors related to mobility limitation 
in community-dwelling older 
Finns. In addition, older persons’ 
perceptions of whether they hoped 
to receive more attention from 
the physician in the management 
of their pain were explored. It 
was shown that musculoskeletal 
chronic pain is often persistent in 
its nature and there is an evident 
need for better pain management in 
community-dwelling older people.
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ABSTRACT
People live longer and pain-related conditions become more common in old age. Since
there are many confounding factors related to pain treatment in older people, concerns
have been raised regarding the management of pain. Pharmacokinetic and pharmadynamic
changes  that  occur  with  normal  ageing,  common multimorbidity  and polypharmacy may
all increase the risk of inappropriate use of pain medication. A better understanding of pain
and its treatment can assist in achieving the goals of optimizing pain management in this
age group.
This study aimed to determine the pattern of analgesic use, the persistence of chronic
pain,  and  factors  related  to  mobility  limitation  in  community-dwelling  older  Finns.  In
addition, older persons’ perceptions of whether they hoped to receive more attention from
the physician in the management of their pain were explored.
This study utilized the data collected in the population-based Geriatric Multidisciplinary
Strategy for the Good Care of Elderly (GeMS). The GeMS was conducted in 2004–2007 and
the participants (n=1000) aged ǃ75 years and living in Kuopio, Finland, were randomly
selected  from  the  population  register  of  Kuopio.  The  participants  were  randomized  to
intervention (n=500) and control (n=500) groups, and both groups were interviewed
annually by study nurses to assess health status and drug use. Those subjects in the
intervention group underwent an annual comprehensive geriatric assessment including
physician’s examination with medication assessment, physiotherapist’s counselling and a
nutritionist’s appointment if needed.
Musculoskeletal chronic pain is often persistent, i.e. the majority of those participants
with  pain  at  baseline  suffered  from  it  also  after  two  follow-up  years.  Almost  half  of  the
community-dwelling older participants were using analgesics and analgesic drugs were
most  commonly  taken  on  an  as  needed  rather  than  on  a  daily  basis.  Females  were  more
commonly analgesic users than men, and paracetamol was the most commonly taken
analgesic drug. The risk of mobility limitation was highest among analgesic users with pain
and it was associated with older age, poor overall health, living alone, sedentary lifestyle
and poor muscle strength. Almost half of older people with musculoskeletal chronic pain
hoped that the physician would be paying more attention to the management of their pain.
This study showed that there is an evident need for better pain management in
community-dwelling older people. Regular pain assessments, evaluation of the
effectiveness of treatment, and developing new strategies to manage pain are needed to
optimize pain treatment. In addition, adjuvant therapy with nonpharmacological
approaches should be encouraged to supplement pharmacological pain management.
National Library of Medicine Classification: WL 704, WL 704.6, WT 500, QV 95, WE 103
Medical  Subject  Headings:  Pain;  Chronic  Pain;  Musculoskeletal  Pain;  Pain  Management;  Drug  therapy;
Analgesics; Acetamonophen; Mobility Limitation; Physician-Patient Relations; Independent Living; Aged;
Aged, 80 and over; Finland
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TIIVISTELMÄ
Ihmiset elävät pidempään ja kipu ja sairaudet yleistyvät vanhuudessa. Monista
sekoittavista tekijöistä johtuen kivun hoito iäkkäillä herättää huolta. Normaalin
ikääntymisen seurauksena tapahtuvat farmakokineettiset ja farmakodynaamiset
muutokset, sekä monet sairaudet ja lääkitykset lisäävät riskiä käyttää kipulääkkeitä
epätarkoituksenmukaisesti. Tietämys kivusta ja sen nykyhoidosta voi auttaa saavuttamaan
tavoitteen kivun hoidon optimoinnista tällä ikäryhmällä.
Tässä väitöstutkimuksessa tarkasteltiin kipulääkkeiden käyttöä, kroonisen kivun
pysyvyyttä ja tekijöitä, jotka ovat yhteydessä liikuntakyvyn rajoittumiseen kotona-asuvilla
iäkkäillä suomalaisilla. Lisäksi selvitettiin toivoisivatko iäkkäät kivun hoitoon enemmän
huomiota lääkäriltä.
Tutkimuksessa analysoitiin aineistoa, joka kerättiin väestöpohjaisessa Hyvän Hoidon
Strategia (HHS) -tutkimuksessa. HHS toteutettiin vuosina 2004–2007 ja yli 75-vuotiaat
osallistujat (n=1000) oli satunnaisesti valittu kuopion väestörekisteristä. Osallistujat
satunnaistettiin interventio (n=500) ja kontrolli (n=500) -ryhmiin, ja tutkimushoitaja
haastatteli molemmat ryhmät vuosittain terveydentilan ja lääkkeiden käytön
selvittämiseksi. Interventioryhmään kuuluville tehtiin vuosittain geriatrinen arviointi,
johon kuului lääkärin tutkimus ja lääkehoidon arviointi sekä fysioterapeutin neuvonta ja
ravitsemusterapeutin tapaaminen tarvittaessa.
Tutkimuksen mukaan krooninen tuki- ja liikuntaelinkipu on erittäin pysyvää
luonteeltaan, sillä suurin osa lähtötilanteessa kipua kokevista iäkkäistä kärsi kivuista myös
kahden seurantavuoden aikana. Lähes puolet kotona-asuvista iäkkäistä käytti
kipulääkkeitä ja suurin osa käyttäjistä käytti kipulääkkeitä vain tarvittaessa. Naiset
käyttivät kipulääkkeitä yleisemmin kuin miehet ja parasetamoli oli käytetyin kipulääke.
Liikuntakyvyn rajoittumisen riski oli suurin kipulääkkeiden käyttäjillä, joilla oli kipuja ja se
oli yhteydessä korkeampaan ikään, huonoksi koettuun terveyteen, yksin asumiseen,
vähäiseen liikuntaan ja huonoon lihasvoimaan. Lähes puolet kroonista tuki- ja
liikuntaelinkipua kokevista iäkkäistä toivoi, että lääkäri kiinnittäisi enemmän huomiota
kivun hallintaan.
Tutkimus osoitti että kotona-asuvat iäkkäät tarvitsevat ja haluavat parempaa kivun
hoitoa. Säännöllistä kivun ja hoidon tehon arviointia sekä uusien kivunhoitostrategioiden
kehittämistä tarvitaan kivun hoidon optimoimiseksi kotona-asuvilla iäkkäillä. Lisäksi
lääkkeettömien liitännäishoitojen käyttöä tulisi edistää lääkkeellisen kivun hoidon tukena.
Luokitus: WL 704, WL 704.6, WT 500, QV 95, WE 103
Yleinen suomalainen asiasanasto: kipu; krooninen kipu; kivunhoito; lääkehoito; kipulääkkeet; parasetamoli;
likuntarajoitteisuus; hoitosuhde; kotona asuminen; ikääntyneet; vanhukset; vanhuus; Kuopio; Suomi
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“Educating the mind without educating
the heart is no education at all”
Aristotle (384 BC – 322 BC)
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Definitions of key terms
Analgesic drug
In this thesis, the term analgesic drug is used to refer to the ATC-classses M01 (anti-
inflammatory and anti-rheumatic products), M02 (topical products for joint and muscular
pain) and N02 (analgesics, including opioids). Low-dose aspirin, specific antirheumatic
agents and anaesthetics are excluded.
Chronic pain
The term chronic pain is used when referring to pain that persists uninterrupted for at least
three months.
Community-Dwelling
The term community-dwelling refers to older people who are living at home or in
circumstances comparable to home, not in assisted living facilities, nursing homes, long-
term care facilities, hospitals or other types of  institutional accommodation where they are
assisted also at night-time.
Mobility limitation
In the literature review, the term mobility limitation refers to mobility restriction that has
been determined with self-report or physical performance test. In the methods and results
sections, the term refers to mobility difficulties measured with the Timed Up and Go test.
Older
In this thesis, the term older refers generally to persons aged ǃ75 years, but the literature
review includes some studies concerning younger people because of the limited number of
studies focusing on older age groups.
Over-the-counter (OTC) drug
Drug that can be purchased from pharmacies without a prescription. The term non-
prescription drug may also be used.
Prescription drug
Drug dispensed from pharmacy only on presentation of a prescription from a physician.
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11 Introduction
Life expectancy is lengthening in most developed countries and the proportion of older people
is growing rapidly. In 2010, approximately 17.5% of the Finnish population was aged ǃ65 years
and this share is estimated to increase to 26.2% by the year 2040 (Official Statistics of Finland,
2012). In demographics, the definition of an older person has been traditionally ǃ65 years since
this is the common retirement age, but the problems related to aging generally occur later in
life. Morbidity, mortality and social problems increase rapidly after the age of 75 (American
Geriatrics Society, 2009). Lengthened life expectancy and later onset of chronic diseases and
disabilities support the proposal to alter the age limit of older people so that it should refer to
individuals aged 75 years or more (Christensen et al., 2009).
Pain and pain associated co-morbidities, such as cancer, musculoskeletal conditions,
neuropathies and vascular diseases, become more common as the individual approaches old
age. Adaptation to painful stimuli and injury may be impaired with advancing age, resulting in
a substantial vulnerability to suffer persistent pain (Gagliese and Melzack, 2013). Pain or its
inadequate treatment exerts a number of adverse consequences on functional, cognitive,
emotional and social well being of older people. In particular, restrictions in functional capacity
and mobility threaten older persons’ ability to live independently in the community (Guralnik
et al., 1994, Sheppard et al., 2013). In addition, pain causes enormous economic costs for society.
It is one of the most common reasons for seeking medical treatment and pain related
restrictions in functioning and mobility increase the need for institutional care (Andersson et al.,
1999, Lim et al., 2006, Von Korff et al., 1991, Coyte et al., 1998, Maniadakis and Gray, 2000). If
one considers the individual and societal burden of pain, then its effective management should
have a high priority. Pain and pain-related situations in older people have been studied widely
in  recent  years,  but  there  is  lack  of  information  concerning  the  persistence  of  pain  in  older
people in a longitudinal setting.
Managing pain in older people requires a consideration of a variety of factors that influence
the safety and efficacy of treatment. The assessment and management of pain may be
confounded by multimorbidity, cognitive impairment and attitudes (both professionals’ and
patients’). Furthermore, polypharmacy and age-related changes in pharmacokinetics and
pharmacodynamics complicate the provision of optimal drug therapy (Barber and Gibson, 2009,
McLachlan et al., 2009). Older people are susceptible to suffering the adverse drug reactions
(ADRs) associated with analgesic drugs, such as the adverse gastrointestinal and renal effects
associated with NSAIDs and the central nervous system (CNS) effects encountered with opioids
(Barber and Gibson, 2009, Hersh et al., 2007). Notwithstanding the potential for ADRs, with
individually tailored therapeutic plan, analgesic drugs represent an important component of an
effective pain management strategy (American Geriatrics Society, 2009). More research is
needed  into  the  use  of  analgesics  among  older  people  in  order  to  reveal  problems  and  to
optimize pharmacotherapy in older patients with pain.
Pain is a complex and subjective experience, and there is conflicting evidence about possible
age differences in pain experience. Older people may attribute pain symptoms to the normal
aging process, especially if it is a case of mild aches (Helme and Gibson, 2001). They may adopt
a stoical attitude and have a stringent noncomplaining response criterion resulting in an
underreporting of mild or weak pain symptoms (Yong, 2006). Older person’s attitudes and
beliefs may also influence their help-seeking behaviour, expectations and the successfulness of
pain treatment (Allcock et al., 2007, Cornally and McCarthy, 2011). However, few studies have
focused on older persons’ perception, their hopes and expectations concerning pain
management.
2The purpose of this thesis was to examine the epidemiology of pain and its management in the
Finnish community-dwelling older population. This thesis explored the use of analgesics, the
persistence of chronic pain and older persons’ perception of whether they hoped to receive
more attention from the physician for the management of their pain. In addition, the association
of pain and analgesic use with mobility limitation was examined. Epidemiological information
can help to develop preventive or educational programs and it is important for public decision
makers planning the structure and allocation of the health care resources. Since the analyses of
this study included only community-dwelling older people, also the literature review was
limited to review mainly to non-institutionized older individuals. In addition, the literature
concentrated on pain at musculoskeletal locations rather than other pain conditions because the
pain data used in the studies included in this thesis focused on musculoskeletal pain.
Furthermore, the other pain types (such as neuropathic pain, chest pain and abdominal pain)
are often treated with different types of drugs to those investigated in this thesis. However, the
literature was not strictly restricted because of the limited number of studies focusing on older
age groups and certain topics.
32 Review of the Literature
2.1 PAIN IN COMMUNITY-DWELLING OLDER PEOPLE
2.1.1 Prevalence, types and sites of pain
The definitive prevalence of pain is difficult to determine in older people. Differences between
studies lead to wide variations in prevalence, because the prevalence of pain is influenced by
many factors e.g. country and population studied, type and methods of study, pain definitions,
type and sites of pain, time period of pain examined, methods used etc. (Abdulla et al., 2013). In
addition, since pain is a subjective experience, it is extremely difficult to measure it objectively.
However, pain is highly prevalent among the aging population and many of the conditions that
impact on general health and occurrence of pain are more common in older individuals. There
are many epidemiological studies demonstrating that the prevalence of any pain complaints
varies in a range between 33% and 74% in community-dwelling older people aged 70 years or
more (Bassols et al., 1999, Bergh et al., 2003, Blay et al., 2007, Brattberg et al., 1996, Brochet et al.,
1998, Jakobsson et al., 2003, Pitkälä et al., 2002, Reyes-Gibby et al., 2002, Thomas et al., 2004).
The  time  window  of  pain  complaints  varied  from  the  past  two  weeks  to  the  past  12  months.
Furthermore, the prevalence of chronic pain (duration of at least 3 months) varies from 24% to
62% in older populations (ǃ75 years) (Bergh et al., 2003, Blyth et al., 2001, Elliott et al., 1999,
Jakobsson, 2010).
It is unclear whether the prevalence of pain increases or decreases with age, especially in old
age. It has been suggested that there is a peak or plateau in the prevalence of pain by age 65 and
a decline in reported pain in the age groups of 75–84 years and 85+ years (Helme and Gibson,
2001). However, in the study of Jakobsson, Klevsgard et al. (2003) the prevalence of pain
increased among older people living in their own home, being 36% for those aged 75–84 years,
41% for those aged 85–89 years and 48% in the oldest age group (90+ years). Similar results were
shown also in Jakobsson’s later study (2010). Brattberg, Parker et al. (1996) reported that the
prevalence of pain decreased among women in the older age groups (77–98 years) but did not
substantially change among men. Contrasting results were reported by Blyth, March et al.
(2001) and Thomas, Peat et al. (2004) since their studies detected an increase in pain prevalence
among women and a decrease in men in the older age groups, but it should be noted that there
were  only  two age categories  with  individuals  aged 75  years  or  more  in  both studies  and the
oldest age groups contained fewer participants than younger age groups.
Most studies have demonstrated that pain is more prevalent and widespread among women
than men late in life (Blay et al., 2007, Blyth et al., 2001, Brattberg et al., 1996, Brochet et al., 1998,
Elliott et al., 1999, Helme and Gibson, 2001, Jakobsson, 2010, Leveille et al., 2005, Thomas et al.,
2004, Urwin et al., 1998). In addition, older women tend to report more severe pain than men
(Brattberg et al., 1996). The magnitude of sex differences in pain prevalence may depend on
gender-related factors. For example, osteoarthritis and joint pain have been reported to be more
prevalent in women than men (Brochet et al., 1998, Donald and Foy, 2004, Felson et al., 1997).
There is also evidence that women are more willing to report pain than men (Greenspan and
Traub, 2013). One possible reason for sex differences in pain reporting is that the older men
represent a selected sample of survivors because the mortality of men is higher in the younger
age groups (Official Statistics of Finland, 2012). It is important to recognize some confounding
issues related to the pain reports of older people when evaluating pain prevalences. The very
old are often survivors that may experience less pain-causing disease, or they may have a stoic
attitude towards pain even misattributing pain symptoms to the aging process itself (Helme
and Gibson, 2001).
4The types and causes of pain change with age. It has been suggested that pain perception alters
with increasing age and in particular the visceral pain sensation is impaired in older people.
The sensation of visceral pain may change because of several reasons, including impaired A-
Delta fiber nociceptive function, altered serotonin metabolism, and as may their response to
analgesics e.g. increased responsiveness of older individuals to nonopioid analgesic pathways
at the spinal cord level (Moore and Clinch, 2004). In addition, there may be a role for reduced
nitric oxide responsiveness and slower central processing of noxious stimuli. Due to these
changes, older patiens are much more likely than younger patients to present with atypical
types of visceral diseases; e.g. there may be an absence of pain in silent ulcerations and life-
threatening GI-bleeding (Hilton et al., 2001). Furthermore, variations in chest pain complaints
related  to  myocardial  infarction  occur  more  frequently  in  older  pople.  In  particular  the
incidence of silent or painless myocardial infarction increases and is estimated in a range of 35–
42% in people older than 65 years (Gibson and Helme, 2001). These atypical presentations of
pain increase the risk of delay in the diagnosis and treatment of underlying conditions.
Furthermore, the prevalence of any headaches tends to decline with increasing age, particularly
the prevalence of migraine heacache decreases after the age of 40 (Lipton et al., 2001, Prencipe et
al., 2001) (Figure 1). Despite a decline in headache prevalences with age, the tension-type
headache continues to be relatively frequent in older populations. According to Prencipe, Casini
et al. (2001), tension-type headache is the most common primary headache type in older people
aged 65–96 years; the one year prevalence rate for tension-type headache was 45% as compared
with 11% for migraine headache and 3% for other headaches.
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Figure 1. Adjusted age-specific prevalence of migraine by sex (Lipton et al., 2001).
Neuropathic pain (pain associated with the somatosensory system) becomes more common in
old age, because the frequency of diseases evoking neuropathic pain, such as herpes zoster and
diabetes, increases with age (Cruccu and Truini, 2010). It is difficult to diagnose neuropathic
pain and especially distinguishing it from nociceptive pain is challenging often requiring
analysing the exact quality of somatosensory abnormalities (Baron et al., 2010). Neuropathic
pain involves heterogeneous mechanisms of pain and it is most commonly treated with drugs
that decrease the sensitivity of nociceptive receptors or desensitize the pain transmitting C-
fibers (e.g. anti-depressants and anti-epileptics). In addition to neuropathic pain, there is
evidence that fibromyalgia becomes more prevalent with advancing age (Bannwarth et al., 2009,
Santos et al., 2010). In the study of Branco, Bannwarth et al. (2010), the prevalence of
fibromyalgia appeared to increase from approximately 2% to 7% between age groups 35–44
5years and 74–85 years but subsequently the prevalence declined dramatically. However, in an
other study the presence of fibromyalgia (based on the criteria of the American College of
Rheumatology) was rather uncommon (0.3%) in community-dwelling older people (ǃ70 years),
although higher tender point counts, multisite pain and widespread pain were relatively
common (Eggermont et al., 2010).
Musculoskeletal conditions (such as osteoarthritis, rheumatoid arthritis, osteoporosis and
low back pain) are the most common cause of severe long-term pain and the prevalence of these
conditions increases markedly with age (Woolf and Pfleger, 2003). For example there is a report
that the prevalence of musculoskeletal pain can be as high as 62% in older people (Grimby et al.,
1999). The musculoskeletal pain in older patients is often degenerative in its nature and it is
most commonly a consequence of osteoarthritis, a condition that increases substantially in old
age (Palazzo et al., 2014, Yamada and Thomas, 2011) (Figure 2). Age has been shown to be the
strongest predictor for osteoarthritis development; this is thought to be due to insufficient
repair mechanisms, hormonal changes and the cumulative impacts of a variety of noxious
environmental exposures (Petersson and Jacobsson, 2002).
Figure 2. The changes in the prevalence of musculoskeletal conditions with age (Palazzo et al.,
2014).
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6The knees are the most common pain site in community-dwelling older people (Lichtenstein et
al., 1998, Thielke et al., 2012, Thomas et al., 2004, Urwin et al., 1998). It seems that with
advancing  age,  pains  and  aches  move  from  the  upper  body  to  lower  body  parts.  A  Finnish
study that analyzed pain complaints in general practice clients revealed that the most common
pain site in adults aged 20–39 years was the head (33%) whereas in older people (70+ years) the
most common pain site was the lower limbs (41%) (Mäntyselkä, 1998). Pain in hips, knees, most
joints and multiple areas seems to increase with age while in other areas there is only a minor
change (Figure 3) (Urwin, Symmons et al 1998). In addition, the pain experience becomes more
disabling with age, if this is measured by its interference with daily activities (Figure 4)
(Thomas et al., 2004). The most common pain sites after the knees are back and shoulders, but
the frequency order of neck, hip, foot and hand pain has varied in different studies
(Lichtenstein et al., 1998, Thielke et al., 2012, Urwin et al., 1998).
Figure 3. The prevalence of musculoskeletal pain symptoms (more than one week in the past
month) according age groups. Modified from the study of Urwin et al. (1998).
Figure 4. The proportion of regional pain sufferers (for one day or longer in the past 4 weeks)
reporting pain interference subdivided into different age groups. Modified from the study of Thomas
et al. (2004).
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72.1.2 Persistent and chronic pain
Pathophysiologic processes causing chronic pain differ from those involved with acute pain.
Repeated stimulation of pain pathways induces hypersensitization of the pain-sensing system
due to physiochemical changes in neural pathways of the spinal cord and this causes a
simultaneous increase in the resistance to intrinsic inhibitors of pain (Katz and Barkin, 2010).
Older people are particularly vulnerable to suffer prolonged pain problems since the
regenerative capacity of the body and adaptation to painful stimuli become impaired with
advancing age (Gagliese and Melzack, 2013). The terms persistent pain and chronic pain are
often used interchangeably in the literature to refer to a painful experience that continues longer
than the expected healing time for an injury or illness, or if there is no injury or illness, but the
pain persists uninterrupted for at least 3 to 6 months (American Geriatrics Society, 2002). The
cut-off points of 3 and 6 months are most commonly used in research, but even a period as long
as 12 months has been used (Main and Spanswick, 2001). The use of a longer period may be
reasonable in some cases, for example to determine chronic pain after a surgical procedure.
However, the definitions differ when they are used to categorize certain pain syndromes.
Persistent pain may refer to patients with neck or back pain who do not recover from the
original acute pain but they exhibit none of the characteristics of chronic pain syndrome (Long,
2013). In other words, patients with persistent pain remain functional and they do not develop
psychological abnormalities despite the pain symptoms remaining more or less constant for
years.  Chronic  pain  syndrome  is  characterized  by  the  chronicity  of  pain  complaints  and  it  is
often complicated and worsened by other comorbid conditions and psychological distress. Due
to its multidimensional nature, chronic pain cannot be attributed simply by nociception because
there might be also sociodemographic, genetic and affective factors influencing pain perception
(van Hecke et al., 2013). Unfortunately, some older persons associate the term “chronic pain”
with negative stereotypes associated with psychiatric problems, futility of treatment,
malingering or drug-seeking behaviour and therefore the term “persistent pain” may be more
advisable for use with older persons (American Geriatrics Society, 2002).
2.1.3 Pain assessment
The patient’s self-report is the gold standard for assessing the existence of pain and its intensity
since there are no objective biological markers or diagnostic tests that measure pain (American
Geriatrics Society, 2002). Pain assessment tools, such as questionnaires and rating scales, have
been developed to measure both the quantity and the dimensions of pain. It has been claimed
that  the  commonly  used  pain  assessment  tools  are  valid  and  likely  to  work  also  in  older
patients, even in the presence of mild to moderate cognitive impairment (Bergh et al., 2000,
Ferrell et al., 1995, Herr et al., 2004). However, sensory impairments (hearing or vision),
dysphasia and aphasia should be noted as they can complicate the assessment of pain and their
presence may require adopting modified methods with which to assess pain (Herr, 2011).
The use of common pain assessment tools requires language and cognitive skills that are
often  diminished  in  the  presence  of  cognitive  impairment.  A  number  of  pain  assesment  tools
have been developed for patients with advanced cognitive impairment and an inability to self-
report (Zwakhalen et al., 2006). However, tools based on observation of behaviour may not be
unambiguous because behaviours associated with pain cues can also be signs of physiologic or
emotional distress. The tools believed to have the strongest conceptual and psychometric
support as well as clinical utility include The Assessment of Discomfort in Dementia Protocol,
Checklist of Nonverbal Pain Indicators, The Doloplus 2, Nursing Assistant-Administered
Instrument to Assess Pain in Demented Individuals, The Pain Assessment Scale for Seniors with
Severe Dementia and The Pain Assessment in Advanced Dementia Scale (Herr et al., 2006).
However,  because  the  focus  of  this  thesis  was  on community-dwelling older  persons  without
severe cognitive impairment, these pain assessment tools will not be described further here.
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Unidimensional pain scales help to define the intensity of pain. The Visual Analogue Scale
(VAS) consists of a 100mm horizontal or vertical line anchored by verbal descriptors such as ‘no
pain’ and ‘worst pain possible’; this scale has been widely used to measure pain intensity in
younger patients, but it is probably not the best choice for older adults (Gagliese et al., 2005,
Pesonen et al., 2008, Peters et al., 2007). VAS has a higher failure rate and it is less preferred by
older people (Hadjistavropoulos et al., 2007).
Numeric  Rating  Scale  (NRS)  has  both  written  and  verbal  forms  and  it  can  have  variety  of
scale ranges (including 0–5, 0–10, 0–20 and 0–100). Patients rate their pain intensity e.g. on the
scale of 0 to 10 where 0 indicates ‘no pain’ and 10 represents ‘most intense pain imaginable’.
NRS is suitable and often preferred by older people who are able to self-report, but some older
adults may experience difficulties with the scale because it requires abstract thought
(Hadjistavropoulos et al., 2007, Wood et al., 2010). It has been claimed that a verbally
administered NRS can be a good choice if the patient’s poor vision causes difficulties with
visual scales and it is also believed to be more suitable for some cognitively impaired patients
(Herr, 2011).
Faces Pain Scale (FPS) includes pictures of faces ranging from a neutral happy face (no pain)
to a grimacing face (worse pain) and it may assess a broader construct of pain affect than pain
intensity, but it requires abstract thinking and has been problematic for older people with
cognitive impairment (Hadjistavropoulos et al., 2007).
Probably the most widely recommended tool for use with older people is the Verbal
Descriptor Scale (VDS) (Herr et al., 2004, Pesonen et al., 2008). VDS is available in a variety of
scale  types,  but  the  most  simple  version  includes  only  four  words  to  describe  pain  intensity;
none, mild, moderate and severe. VDS has strong psychometric support, it is preferred, and
able to be completed by most older patients, even those with impaired cognition (Herr et al.,
2004, Peters et al., 2007, Taylor et al., 2005). However, VDS requires also abstract thinking and
additionally it poses greater demands on language capabilities (Hadjistavropoulos et al., 2007).
Multidimensional pain tools
Unidimensional pain scales do not provide information about pain locations, interference or
qualities, and therefore multidimensional methods have been developed to evaluate those
aspects of pain. This is a reasonable approach because of the subjective, complex and
multidimensional nature of pain. An interdisciplinary consensus statement has recommended
for cognitively intact older adults that the assessment should be conducted with the Brief Pain
Inventory (BPI) combined with the McGill Pain Questionnaire (MPQ) (Hadjistavropoulos et al.,
2007).
BPI is a short, self-administered questionnaire designed to assess the severity of pain and
how much it interferes with daily routines (Cleeland and Ryan, 1994). Respondents rate their
worst, least, average, and current pain intensity and also rate the degree to which pain
interferes with 7 domains of functioning (general activity, mood, walking ability, normal work,
relations with other persons, sleep, and enjoyment of life) on a scale of 0 to 10. BPI has been
validated  in  over  30  languages.  Not  only  does  it  have  good  psychometric  properties  but  it  is
also simple to administer and score; unfortunately it does not evaluate the affective dimension
or qualitative aspects of pain (Hadjistavropoulos et al., 2007).
MPQ includes 20 categories of adjectives to describe the sensory, affective, evaluative and
miscellaneous pain experiences (Melzack, 1975). Patients are asked to select those words that
best describe their feelings and sensations at that moment. MPQ is valid and reliable for use in
older people suffering chronic pain, but it is not recommended for illiterate and cognitively
impaired persons (Gagliese and Melzack, 2003, Hadjistavropoulos et al., 2007). Short forms of
both questionnaires have been developed and validated to simplify their use for clinical and
research purposes (Melzack, 1987, Cleeland, 2009).
9The comprehensive assessment of older persons with pain should also include measures of
physical disability, interference of pain with daily life and psychological distress, since pain is
modulated by psychological state and functional status (Gagliese and Melzack, 2013). Objective
measures of  these constructs are in frequent use; there are also pain assessment tools that
include some of those dimensions, e.g. Functional Pain Scale (Gloth III et al., 2001), Pain
Disability Index (Tait et al., 1990), Geriatric Pain Measure (Ferrell et al., 2000), Multidimensional
Pain Inventory (Kerns et al., 1985), Western Ontario and McMaster Universities Osteoarthritis
Index (Bellamy et al., 1988) and Arthritis Impact Measurement Scale (Meenan et al., 1980).
2.1.4 Older people’s experience of pain and its treatment
Being old and suffering pain is a higly subjective experience. Older persons’ attitudes (affective
response to an object) and beliefs (ideas and ideals held by individuals) about pain, play an
important role in influencing how a patient experiences pain, and these include pain intensity,
psychological distress, coping strategies and functional impairment (Abdulla et al., 2013, Yong,
2006). It is a common belief among older adults that pain is a normal part of aging (Cornally
and McCarthy, 2011). Furthermore, especially pain-related stoicism (adopting an indifferent
attitude towards pain) seems to be particularly evident in the older population and it has been
implicated in the underreporting of pain (Helme and Gibson, 2001). Thus, the association
between  age  and  self-reported  pain  may  be  mediated  by  stoic  and  cautious  attitudes,  which
suggests that the lower report of pain severity commonly described in patients of advancing
age is due more to attitudes than age per se (Yong, 2006). Inappropriate stoicism can be
perceived when patients’ self-reports of pain are incongruent with their behavior or with their
reported need for (or consumption of) analgesic therapies (Spiers, 2006). This phenomenom
may result in a conflict between professionals trying to alleviate suffering by ensuring that there
is appropriate pain management and their desire to be supportive of patient’s point of view, i.e.
trying to convince patients that their experience is being understood and appreciated. In the
light of previous studies, there seems to be a risk that these underlying attitudes and beliefs
held by older people act as barriers to effective pain management.
On the other hand, a stoical attitude may help to cope with pain in daily life. The older age
group (60–81 years) has reported better mood scores and a higher quality of life scores than
younger age groups (18-39 or 40–59 years) although they had higher pain intensity scores,
longer duration of pain and a higher percentage of chronic diseases. (Rustoen et al., 2005). In
addition, it has been demonstrated that there are two types of older people experiencing pain
that express greater satisfaction in life; these have been classified as ‘confident and serene’ and
‘competent and proud’ (Blomqvist and Edberg, 2002) Older people seem to assess the type of
pain which restricts their daily living as a greater problem than the actual pain itself. They may
conceptualise health as representing independence and being able to carry out everyday tasks
rather than as the state of health of the body. Older persons may consider themselves as being
healthy  even  though  they  have  painful  joints  and  the  presence  of  symptoms  may  not
compromise their sense of being well, as long as their brain remains functional and they can be
as independent as possible (Grime et al., 2010). Unfortunately, older people’s autonomy
becomes threatened by restricted physical activity leading to impaired social participation;
aspects which have been described as an inevitable consequence of pain in old age (Mackichan
et al., 2013). Blomqvist and Edberg (2002) identified also two groups of older people in pain
who expressed primarily dissatisfaction. Those who were called ‘misunderstood and
disappointed’ and ‘resigned and sad’ felt dissatisfaction not only due to the pain itself but also
because their significant others did not listen to or did not take seriously their complaints.
Feeling that they were considered as a nuiscance increased their suffering. Thus, it is important
that older people’s experiences of pain are acknowledged as a true problem and their pain and
possible depressive emotions are identified and treated by multidimensional strategies.
Many older people normalizing pain probably choose not to seek treatment for their pain
problems. There is a report that stoic older adults (ǃ60 years) who were not willing to disclose
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their pain to others were also less likely to seek help from health care professionals (Cornally
and McCarthy, 2011). They found that female sex, increasing age, severe pain, living alone and
higher  education were  associated with higher  levels  of  expressing a  need for  help for  chronic
pain. In addition, those who believed that their pain had an organic cause were more likely to
seek help. These findings seem reasonable because women tend to use health-care services more
than men and usually the number of diseases increases with age so that there may be also other
reasons in addition to pain requiring help from a physician (Redondo-Sendino et al., 2006).
Furthermore, people probably handle mild pain problems by themselves and a person living
alone  may  lack  the  social  support  of  a  partner  and  thus  may  be  more  inclined  to  seek
professional help. Previous studies have demonstrated that people with higher education are
more likely to engage in healthy behavior which can partly explain why higher education was
associated with help-seeking behavior related to pain (Boylan et al., 2011). To an older person, it
may feel also more acceptable to seek care for pain problems for which there is an apparent
reason in comparison to help for pain with no clear cause.
Older patients’ expectations of pain treatment are often difficult for clinicians to determine,
but there are some studies into this topic. Older patients with musculoskeletal pain often feel
information on prognosis as important and therefore it may be worthwhile to ask during the
consultation whether the patient wants to know about the likely course of his/her condition
(Mallen and Peat, 2009). In a small-scale exploratory study including older and younger
participants with pain, patients were asked to prioritize reasons for their pain treatment; the
main reasons were physical or functional improvements, including less pain, pain-free periods,
and being able to do more everyday activities (Allcock et al., 2007). Sometimes merely the
opportunity to talk frankly about pain, its consequences and to alleviate patient concerns, can
represent a useful therapeutic intervention for older people (Sofaer et al., 2005).
The value of hope should be noted in pain treatment, because it is claimed that hopefulness
fosters coping strategies that increase participation in treatment regimens and strengthen the
belief that difficulties can be overcome (Hammer et al., 2009). Pain patients often feel that the
most discouraging outcome of clinic visit is to be told that nothing can be done to alleviate their
pain problem (Petrie et al., 2005). This kind of outcome in the consultation situation may lead to
unnecessary despair and suffering of the patient. Thus supportive interventions responding to
the hopes of pain patients may be recommended as facilitating the management of pain.
However, older people’s hopes in relation to pain and pain treatment have rarely been studied.
2.2 EFFECT OF PAIN
Living with pain is a significant burden that negatively affects an older patient's psychosocial
and physical well-being. The adverse consequences of pain include mobility and functional
disability (Leveille et al., 2002, Shah et al., 2011), increased risk of falling (Stubbs et al., 2014),
decreased cognitive function (Moriarty et al., 2011), increased anxiety and depression (Arola et
al., 2010), poor self-rated health (Reyes-Gibby et al., 2002), loss of appetite (Bosley et al., 2004),
sleep disturbances (Chen et al., 2011), disruptions in social relationships (Peat et al., 2004) and
decreased quality of life (Hawkins et al., 2013). However, only pain-related mobility limitation,
self-rated health and quality of life will be discussed here in more detail since those are crucial
factors with respect to this thesis.
2.2.1 Mobility
Physical inactivity and poor mobility have been found to display an association with increased
mortality risk in older people (Newman et al., 2006, Äijö et al., 2002). Musculoskeletal pain,
especially in the lower extremities (hip, knee, calf, ankle, foot) and back, has a detrimental
impact on postural balance and mobility (Leveille et al., 2002, Jones et al., 2012). Severe pain
leads to a restriction of painful movements and changes in normal movement patterns (Hurwitz
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et al., 1997). This can create a viscious circle, with compensations causing atrophy of the
muscles  which further  increases  pain and impaired balance  resulting in  even further  mobility
restrictions (Visser et al., 2005). The fear of pain has been described in patients suffering from
pain and it may accentuate the avoidance cycle. This can enhance safety seeking behaviours
such as avoidance and hypervigilance, which although these behaviours can be considered as
beneficial in the acute pain stage, they paradoxically worsen the problem in the case of long-
lasting pain (Leeuw et al., 2007). In addition to a distinct fear of pain, the fear may be directed to
other pain related outcomes such as fear of movement (kinesiophobia) or of falling.  A recent
review  provided  evidence  that  pain  was  associated  with  fear  of  falling  and  avoidance  of
activities which could involve falling in community dwelling older adults (Stubbs et al., 2014).
These underlying factors may result in a vicious circle which is hard to break.
Older persons represent a significant group of people at risk for suffering pain and mobility
problems sufficiently severe to influence daily functioning. Previous studies have demonstrated
that musculoskeletal pain is significantly associated with the development of mobility
disabilities in community-dwelling older people (Buchman et al., 2010, Shah et al., 2011).
Furthermore, limitations in mobility threaten the older person’s ability to live independently in
the community. Leveille et al. (2002) reported that pains in the lower extremities were the main
causes of disabilities in lower extremity mobility tasks e.g. bathing, using the toilet, walking,
and stair climbing. The results linking musculoskeletal pain to mobility limitations raise the
possibility that treatments which successfully decrease musculoskeletal pain may prevent the
development of mobility disabilities in older persons. However, the biological pathways
between musculoskeletal pain and mobility disability are far from clear and further research is
needed to confirm that effective pain management strategies are able to prevent or delay the
development of mobility disabilities.
2.2.2 Self-rated health
Good perceived subjective health and well-being are important in everyday life as ways to
promote successful ageing. It has been demonstrated that self-rated health is an important and
independent predictor of morbidity and mortality (Bardage et al., 2005, Tamayo-Fonseca et al.,
2013). This phenomenon has been reported also in the very old (90+ years) population (Tiainen
et al., 2013). Self-rated health is typically assessed using a single item: Overall, how would you
rate  your  general  health  status?  and  5  response  options  from  poor  (1)  to  excellent  (5)  are
possible (Eriksson et al., 2001). The study of Bardage, Pluijm et al. (2005) documented that those
individuals with either fair or poor self-rated health were more than twice as likely to have
musculoskeletal diseases. Furthermore, the adverse impact of pain on self-rated health is well
documented in general and also in older populations, even when clinical health status, access to
medical care, and socidodemographic characteristics have been taken into account (Mäntyselkä
et al., 2003, Reyes-Gibby et al., 2002). In addition to those with pain, there was about the same
risk  in  those  individuals  with  with functional  limitations  perceiving themselves  to  be  in  poor
health (Reyes-Gibby et al., 2002). The strong association between pain and self-rated health, as
well  as  with  functional  status  found in  the  study of  Reyes-Gibby et  al.  (2002)  emphasizes  the
importance of treating and controlling pain even although self-rated health may be a
multidimensional construct that includes pain as only one of its dimensions.
2.2.3 Quality of life
Quality of life (QoL) is an multidimensional indicator of everyday life and it is negatively
affected by functional and health complaints. Overall QoL takes a broader view than the health-
related QoL measure that concentrates on functioning, well-being and general health status and
is most commonly used in health care contexts (Borglin et al., 2005).  The Short Form Health
Survey containing 36-items (SF-36) is the most commonly used health-related QOL measure,
but there are several alternatives to the SF-36 (Coons et al., 2000). The choice of a suitable
measure depends on a variety of factors including the characteristics of the population and the
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environment in which the measurement will be done. A shorter and more practical version of
SF-36 is the 12-item Short Form Health Survey (SF-12); this may be more suitable for older
persons, because the instrument is easy to administer and does not contain questions that are
related to work (Jakobsson et al., 2003, Resnick and Nahm, 2001).
Pain has been found to be the strongest musculoskeletal correlate in the health-related QoL
in persons with osteoarthritis (Laslett et al., 2012). Those who suffer from pain are at high risk of
decreased QoL and should they also need help to manage daily routine tasks (perhaps because
of functional limitations or other complaints) then this may result in an even lower QoL
(Jakobsson et al., 2007). In the study of Borglin, Jakobsson et al. (2005) pain was significantly
associated with low overall present QoL as well as with low physical and mental health-related
QoL. A mobility impairment was associated with low physical health-related QoL and low
present QoL. This emphasizes the need to focus on pain in older people and to take actions to
improve their QoL by preventing and controlling pain and the pain-related mobility limitations.
However, it may not be possible to fully relieve pain and improve functional limitations and in
such a situation the goal of treatment should be towards promoting health and helping to
maintain, even improve, the older person's overall quality of life.
2.3 MANAGEMENT OF PAIN IN OLDER PEOPLE
2.3.1 Pharmacological pain management
Pharmacotherapy plays a central role in the control of pain and the World Health Organization
has developed a recommendation in the form of a three-step ladder (Figure 5), for cancer pain
relief (WHO, 1996). The use of this analgesic ladder has been extended to other kinds of pain,
including persistent pain from noncancer causes. Its educational value and the benefits
resulting from its worldwide dissemination are uncontested, although it can be debated
whether the ladder form is relevant in all pain cases (Vargas-Schaffer, 2010). According to the
steps  on  the  analgesic  ladder  the  treatment  is  adjusted  in  relation  to  pain  intensity  and  the
presence of adverse effects. Non-opioids are suitable alone for mild pain and in the case of
moderate to severe pain they can be combined with weak (step 2) and strong (step 3) opioids. It
is  important  to  consider  that  there  are  several  confounding  factors  associated  with  the
pharmacotherapy of pain in older people. These complicating factors include the large inter-
individual variation in the response to analgesics, the lack of clinical studies in older
populations and the increasing prevalence of comorbidities, polypharmacy, cognitive
impairment and frailty (Koponen et al., 2013, McLachlan et al., 2009). Age-related changes in
physiology may alter the pharmacokinetics and pharmacodynamics of analgesic drugs (McLean
and Le Couteur, 2004, Mitchell et al., 2009) (Table 1). Since pain often has both varied and
multiple underlying physiological processes, it is important to consider the multimechanistic
nature of pain in the treatment i.e. to attempt to match the analgesic’s mechanism of action with
the type of pain. Therefore, in some situations it is reasonable to treat pain according to a more
generalized ‘pain pyramid’ that provides clinical flexibility and patient-individualized care
strategy to achieve better pain management (Raffa and Pergolizzi, 2014). The pain pyramid
consists of four mechanism-based steps and includes the possibility for analgesic switching on
the same step, or movement down steps and initiating therapy with a step 4 agent because it
has an appropriate mechanism of pain relief.
Many analgesic medications are included in lists of inappropriate medications compiled by
expert consensus panels, for example the updated ‘Beers criteria for potentially inappropriate
medication use in older adults’ includes multiple agents from the non-steroidal anti-
inflammatory analgesic class (AGS, Beers Criteria Update Expert Panel, 2012). This is
reasonable since older people are at increased risk of suffering adverse effects from analgesic
medications. It is important to recognize the clinical pharmacology of ageing and analgesics
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because an understanding of advantages and disadvantages of analgesic medications can help
with drug and dose selection for older people. Some considerations and recommendations
related to analgesics and older people will be described at the end of this section (Table 2).
Figure 5. The World Health Organization analgesic ladder for treating cancer pain. Modified from
WHO 1996.
Paracetamol
According to the WHO analgesic ladder, the administration of analgesics should start with
nonopioids, most frequently paracetamol (WHO, 1996). Paracetamol represents the first line
analgesic drug therapy for nonmalignant pain in older people. It is an effective drug
particularly  for  musculoskeletal  pain  and  it  is  well  tolerated  causing  few  ADRs  when
recommended limits are followed (a maximum dose of 4g in 24 hours for patients with no
impairments of renal or hepatic function and no history of alcohol abuse) (Abdulla et al., 2013,
American Geriatrics Society, 2009). It should be noted that older people are more likely than
younger adults to use concominant medications which can induce drug-metabolizing enzymes
and  are  more  likely  to  be  frail  (both  conditions  can  cause  an  accumulation  of  the  toxic
metabolite of paracetamol), therefore it is reasonable to use less than 4 grams in this subgroup
(O'Neil et al., 2012). The Finnish expert consensus recommendation for older people is no more
than 3 grams in 24 hours in continuous use, and a maximum dose of 4 grams is acceptable only
for short-term use (Fimea, 2014). This reduction in recommended maximum daily dose is
reasonable since a recent Finnish study found that the administration of paracetamol resulted in
higher exposure to the drug in older people due to the lower clearance and reduced apparent
volume of distribution (Liukas et al., 2011).
Despite being one of the most widely used analgesics, the analgesic mechanism of paracetamol
is still unclear. Paracetamol is not a peripheral anti-inflammatory agent but instead it is
centrally acting. It is well absorbed after oral administration (Davis and Srivastava, 2003, Smith,
2009). Furthermore, it has few drug interactions because it is metabolized via glucuronidation.
Although paracetamol is a relatively safe drug, it has a fairly narrow therapeutic index; in fact
the major limitation of paracetamol is that it has an upper dosing limit (Mitchell et al., 2009).
Paracetamol overdoses are associated with hepatotoxicity and the risk factors for paracetamol
overdose include older age, malnutrition, alcohol abuse and underlying liver disease (Myers et
al., 2008). It has been demonstrated that the proportion of accidental paracetamol overdoses
increases with older age (Myers et al., 2007). There may be several reasons for paracetamol
hospitalizations of which accidental overdose is one important cause, especially in the older
patients. Thus 50% of all over 70 years olds requiring hospitalization for paracetamol-related
STEP 1
Mild pain
Non-opioid e.g.
paracetamol,
NSAIDs
± Adjuvant e.g
antidepressant or
anticonvulsant
STEP 2
Moderate to
strong pain
Weak opioid e.g.
buprenorphine,
codeine, tramadol
± Non-opioid
± Adjuvant
STEP 3
Severe pain
Strong opioid e.g.
morphine,
oxycodone,
hydromorphone,
fentanyl
± Non-opioid
± Adjuvant
Increasing or persisting pain
Table 1. Physiological changes and clinical consequences in older people. Data gathered from Abdulla, Adams et al. 2013, AGS 2009,
Christo, Li et al. 2011, and Mitchell Hilmer et al. 2009.
PHYSIOLOGICAL
CHANGE WITH NORMAL AGEING
CLINICAL CONSEQUENCE EFFECT ON  PAIN PHARMACOTHERAPY
GI-Absorption
     Delayed gastric emptying
     GI tract peristalsis љ
     GI tract blood flow љ
Alteration of drug absorption has little clinical significance
Risk for GI-related ADRs ј
Effect of continuous release enteral agents ј
Bioavailability of morphine ј
Opioid related gut mobility disturbanceј
Distribution
     Body water љ from 15% to 10%
     Body fat ј from 20% to 40%
     Plasma proteins љ
Concentration of water soluble drugs ј
Accumulation and half-life of lipid soluble drugs ј
Free fraction of drugs that are highly bound to proteins ј
Drug-drug interaction risk ј
Free fraction of highly protein-bound drugs
such as acetylsalicylic acid, celecoxib and
fentanyl ј
In older people the AUC of paracetamol ј
Metabolism
     Liver mass љ
     Hepatic blood flow љ
     Functioning liver cells љ
First pass metabolism љ
Oxidative reactions (phase I) љ
Prolonged half-life
Conjugation (phase II) usually preserved
Activity of acetylsalicylic acid esterase љ
Difficult to predict precise effect in an individual
In frail patients: Phase I and II metabolism of
paracetamol љ paracetamol hepatotoxicity ј
Metabolism of morphine (II), fentanyl (I),
codeine (I) and celecoxib (I?) љ
Renal excretion
     Renal blood flow љ
     Glomerular filtration љ
     Tubular secretion љ
Excretion of drugs and metabolites љ Accumulation and
prolonged effects ј
Reduced clearance and increased t½ of
paracetamol and its metabolites, ASA,
ibuprofen, celecoxib, oxycodone, fentanyl,
morphine metabolites and codeine metabolites
Pharmacodynamic changes
     µ-opioid receptor density љ
     and affinity ј
Sensitivity to the therapeutic effects but also to ADEs ј Risk and severity of ADEs ј in people using
e.g. NSAIDs or opioids
Lower opioid doses may be adequate
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problems were admitted due to accidental overdose. This is more than  three times higher than
the figure in general population (15%). One  should  adopt  strategies  to  reduce  the  risk  of
unintentional overdose with paracetamol in the management of pain in older people.
Nonetheless, owing to paracetamol’s advantages in relation to other analgesic drugs, it is likely
that  its  use  will  remain  at  the  top  of  the  recommended  analgesic  drugs  for  administration  to
older people.
Non-steroidal anti-inflammatory drugs
NSAIDs are  analgesics  with  anti-inflammatory and antipyretic  properties  and they are  one of
the most widely prescribed classes of drugs for pain and inflammation (Abdulla et al., 2013).
NSAIDs have a major role in the management of acute and chronic pain syndromes,
particularly for somatic or visceral nociceptive pain (Davis and Srivastava, 2003). These drugs
inhibit the cyclo-oxygenase enzyme (COX) but the differ in their selectivity toward the two
isoenzymes COX-1 and COX-2 (Mitchell et al., 2009). It has been claimed that NSAIDs provide
better efficacy than paracetamol for relief of chronic inflammatory pain (such as the pain
associated with rheumatoid arthritis) and for short-term relief (6 weeks) of osteoarthritis pain
(American Geriatrics Society, 2009). Analgesia with NSAIDs occurs within 4 hours, much
sooner than the anti-inflammatory effects which may take several days even weeks to appear
(Davis and Srivastava, 2003).
Despite their great efficacy to relieve pain associated with many conditions, significant
contraindications and adverse effects, that increase with age, limit their usefulness (Davis and
Srivastava, 2003, Franceschi et al., 2008). NSAIDs  have been associated with the risks of GI,
renal, cardiovascular, haematological and hepatic adverse effects (Hippisley-Cox et al., 2005,
Antman et al., 2007, Barkin and Buvanendran, 2004, Kearney et al., 2006, Rostom et al., 2005).
Previous studies have shown that there is a significant association between the use of NSAIDs
and unplanned hospitalization and deaths in older patients (Griffin, 1998, Price et al., 2014).
With advancing age, particularly the risk for dangerous upper GI hemorrhages and
perforations  seems  to  multiply  (Figure  6).  The  concominant  use  of  NSAIDs  with  low-dose
acetylsalicylic acid (ASA) or with the common anticoagulant drug, warfarin, increases the risk
of serious GI-bleedings (de Abajo and Garcia-Rodriguez, 2008). In addition, the combination of
NSAIDs with corticosteroids, SSRIs (selective serotonin reuptake inhibitors) or paracetamol
may be contraindicated due to increased GI-bleeding risk (American Geriatrics Society, 2009,
Buescher and Meadows, 2004).
Figure 6. The effect of age on the relative risk of upper gastrointestinal hemorrhage or perforation
(Hernández-Díaz and García Rodríguez, 2000, McLean and Le Couteur, 2004).
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The renal adverse effects are mediated by COX-1 and COX-2 as both forms are constitutively
expressed in the kidney. Therefore  both nonselective and COX-2 selective NSAIDs are
associated with renal adverse effects including decrease in renal blood flow leading to a
reversible renal insufficiency, sodium and water retention, hyperkalemia, interstitial nephritis
even acute renal failure (Barkin and Buvanendran, 2004, Barkin et al., 2010). The renal effects of
NSAIDs are mechanism-based, dose-related and all of the drugs exert similar renal function
effects. The concominant use of diuretics, ACE inhibitors, as well as dehydration and older age
are additional risk factors for their renal toxicity (Barkin and Buvanendran, 2004, Davis and
Srivastava, 2003). The cardiovascular risk associated with NSAIDs (traditional and COX-2
selective)  is  particularly  significant  in  older  persons  and  therefore  the  use  of  NSAIDs  for  the
management of persistent pain in older people demands  individualized attention (American
Geriatrics Society, 2009). NSAIDs, especially COX-2 selective compounds, have been associated
with an increased risk  of  serious  cardiovascular  thrombotic  events,  myocardial  infarction and
stroke, and thus it is not recommended that NSAIDs should be used in patients with a high risk
for suffering those events (Katz and Barkin, 2010).
When NSAIDs are used in the management of pain in older people, they should be used at
the lowest effective dose and their use limited to the short-term use (< 2 weeks) only (O'Neil et
al., 2012, Fimea, 2014). Thus, as-needed administration of NSAIDs is preferred, particularly for
intermittent pain. Extended-release NSAIDs are often preferred for chronic pain for the sake of
compliance  although  they  increase  the  risk  of  upper  GI-bleeding  and  renal  dysfunction  as
compared with the short-acting NSAIDs (Davis and Srivastava, 2003, de Abajo and Garcia-
Rodriguez,  2008).  Furthermore,  NSAIDs  should  be  used  one  at  time  and  they  should  not  be
combined with other similar drugs that increase the risk for GI-toxicity, therapeutic redundancy
or cause renal toxicity (Barkin et al., 2010, Davis and Srivastava, 2003). However, it seems that
there are inconsistencies between guidelines and practice, because the study of Johnell, Fastbom
et al. (2008) revealed that the most common potentially serious drug-drug interaction
encountered in older people is concurrent use of ASA with an NSAID.
COX-2 selective NSAIDs were introduced in the hope of reducing NSAID-related adverse
effects, but  they failed due to an increased risk of cardiovascular events and pharmacokinetic
ADRs (Mitchell et al., 2009). In addition, there is mixed evidence showing that COX-2 selective
analgesics may be associated also with adverse GI effects (O'Neil et al., 2012). Two COX-2
inhibitors, rofecoxib and valdecoxib, had to be withdrawn from the market due to concerns
about unacceptable risks of adverse cardiovascular events and celecoxib, that is still available,
has a black-box warning about the increased risk of cardiovascular events (Katz and Barkin,
2010, Nurminen, 2011). According to guideline recommendations, COX-2 selective inhibitors
should be considered only rarely, and with extreme caution, in highly selected older individuals
(American Geriatrics Society, 2009).
A  recommended  strategy  to  reduce  the  risk  of  potential  GI-toxicity  of  NSAIDs  is  co-
administration with gastroprotective agents, such as misoprostol or a proton pump inhibitor
(American Geriatrics Society, 2009). Older people should use a gastroprotective agent with
traditional NSAIDs and with COX-2 selective NSAIDs when they are using low-dose ASA
concurrently (Barkin et al., 2010). Despite the guidelines recommending preventive strategies in
high-risk patients, most patients do not receive co-therapy (Abraham et al., 2005, Laine et al.,
2009).  In  the  study  of  Abraham  et  al.  only  27%  of  high  risk  NSAID  users  had  been  provided
with a strategy to decrease upper GI risk and the minority, 42%, of patients with three risk
factors were receiving protective therapy. Furthermore, incomplete adherence (< 80%) to
protective co-therapy significantly increases the risk of developing upper GI ulcers or bleeding
in patients taking NSAIDs (Goldstein et al., 2006). There is a report that clinicians can reduce the
risk of NSAID-related upper GI events by adhering to recommended guidelines for safer
NSAID prescribing, although the risk can never be entirely eliminated (Abraham et al., 2008).
Nonetheless, the systemic effects of NSAIDs should be noted regardless of gastroprotective co-
therapy, because the above-mentioned agents do not protect from lower GI-damage or
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bleedings (Nagata et al., 2014, Sostres et al., 2013). One useful way to avoid the ADRs associated
with oral NSAIDs is to administer NSAIDs in a topical preparation (Altman and Barthel, 2011,
Zhang et al., 2007, Zhang et al., 2007).
Topical analgesics
The topical analgesic products marketed in Finland include mainly NSAIDs (diclofenac,
ketoprofen or piroxicam) and salicylate derivatives formulated as gels, creams or solutions.
Topical NSAIDs provide analgesia by the same mechanism of action as oral NSAIDS, but due to
their local application and localized site of action, the systemic NSAID exposure is substantially
lower than with oral products (Altman and Barthel, 2011). The precise mechanisms of action of
salicylate derivatives are unclear and their efficacy in pain management has been modest
(Mason et al., 2004). The current Finnish care guidelines recommend topical NSAIDs for
osteoarthritis pain alone or as an adjuvant therapy, because there is evidence that they reduce
pain and increase patient’s ability to function more than placebo (Barthel et al., 2009, Knee and
Hip Osteoarthritis: Current Care Summary, 2012). Clinical trial data published to date support
the analgesic efficacy of topical diclofenac and ketoprofen in patients with osteoarthritis
affecting one or more superficial joints such as those in knees or hands but the data concerning
piroxicam suggests that it has only modest efficacy (Altman and Barthel, 2011). According to
some studies, one topical NSAID, diclofenac, provides effective analgesia for osteoarthritis even
when compared to the oral diclofenac, but because insufficient numbers of older persons have
participated in clinical trials, the risks of this type of therapy remain unclear (Derry et al., 2012,
Fine, 2012, Simon et al., 2009). However, the safety studies have indicated that the most
common ADEs are application-site reactions while serious adverse events are rare and almost
always unrelated to treatment (Altman and Barthel, 2011). Therefore, topical NSAIDs have a
potential role in the treatment of localized non-neuropathic pain in older patients since they
minimize systemic exposure to NSAIDS. However, topical salicylates have not been
recommended in recent guidelines for the management of osteoarthritis since they have shown
less efficacy and are still associated with substantial systemic salicylate exposure and toxicity
(Altman and Barthel, 2011).
Opioids
Opioid analgesics may represent the drugs of choice for older patients who do not respond to
paracetamol or NSAIDs or who cannot tolerate the side effect profiles of these agents. Opioids
inhibit pain pathways by binding to and to activating the µ-opioid receptors in the CNS and
they are recommended in the treatment of moderate to severe pain (O'Neil et al., 2012). Opioids
are available for various routes of administration, such as oral, rectal, sublingual, transdermal,
spinal and intravenous (Davis and Srivastava, 2003). Many guidelines recommend that opioid
therapy should be considered for all patients with moderate-to-severe pain, pain-related
fuctional impairment, or diminished quality of life due to pain (Gloth, 2011). However, opioids
are not appropriate for all patients and the initiation and selection of an opioid for an older
patient needs to take into consideration on the basis of the pain intensity, age-related alterations
in liver and renal function, comorbid conditions, current medications and the patient’s ability to
take the preparation (O'Neil et al., 2012). The lack of a ceiling dose and possibility for titration of
dose are advantages of most opioids but age-related changes in the CNS and GI-tract increase
the sensitivity to both the therapeutic and toxic effects of opioids (Mitchell et al., 2009). For an
older patient, it is recommended that prescribers should initiate opioid therapy at a low dose,
titrate slowly, and monitor drug concentrations and adverse events. Due to their common
mechanism of action, opioids share similar adverse effects, including sedation, drowsiness,
dizziness, nausea, vomiting and constipation. Many of these effects are worse at the time of
opioid initiation or at dose escalation, and may resolve later on, but constipation often need to
be managed with laxative therapy or provision of a peripheral opioid antagonist (Abdulla et al.,
2013).
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Opioid therapy seems to have no effect on mood or to increase the risk of respiratory
depression in older persons as long as low starting doses and proper titration are used
(Podichetty et al., 2003). However, respiratory depression is a particular concern in very old and
frail patients, as well as in individuals with underlying pulmonary conditions such as chronic
bronchitis, multiple sclerosis, chronic obstructive pulmonary disease, etc. or in patients being
treated other CNS drugs that affect ventilation (Pergolizzi et al., 2008). It is uncommon to note
any decline in cognitive function in patients taking stable opioid doses, but this symptom may
appear for one week after a dose increase (Abdulla et al., 2013). However, opioid CNS toxicity is
a  significant  issue  in  older  patients,  where  it  can  present  as  hallucinations,  confusion  and
problems with cognition and these symptoms may occur when opioids are given over the long-
term at high doses, particularly in dehydrated, severely ill patients with renal impairment
(Pergolizzi et al., 2008). This is particularly detrimental for older persons who are at the
increased risk of falling and suffering serious fractures. A higher fracture risk has been
observed in older people who start to receive opioid analgesic therapy or who use high doses or
short-acting opioid preparations (Miller et al., 2011, Saunders et al., 2010). In contrast, the risk of
addiction  or  opioid  abuse  is  probably  not  a  major  concern  in  the  older  population.  Drug-
seeking behaviour and ‘doctor-shopping’ to obtain multiple opioid prescritions i.e. opioid abuse
is not commonly encountered in older persons with nonmalignant pain (Neutel et al., 2013).
There was an increase in the number of prescribers and in defined daily doses of opioids in
cancer/palliative patients, but these patients typically represent a population needing larger
amounts of opioids.
According to the WHO analgesic ladder, weak opioids (such as codeine, tramadol and
buprenorphine) are the second-line option after non-opioids (Figure 5). However, codeine and
tramadol  are  not  the  best  options  for  older  people  (Arnstein  2010).  In  Finland,  codeine  is
marketed only in fixed combination products including paracetamol or ibuprofen and those
ingredients are associated with the previously mentioned risks and daily dose limits. In the case
of tramadol which is a drug that displays also serotonin and noradrenaline reuptake inhibitory
effects, drug-drug interactions with agents affecting noradrenaline and serotonin levels and the
risk for seizures at high doses are problematic in the treatment of older patients (Arnstein,
2010). In addition, it has been claimed that codeine and tramadol may cause more nausea and
constipation than other opioids (Mitchell et al., 2009). Furthermore, codeine and tramadol are
prodrugs that are activated by the enzyme CYP2A6 to morphine and inherent genetic
differences or consumption of medications influencing CYP2A6 may cause large variations in
the efficacy of those drugs (Davis and Srivastava, 2003). The pharmacokinetics of both agents
may change, with age-related alterations leading to accumulation of active metabolites (Katz
and Barkin, 2010).
Buprenorphine  has mixed agonist-antagonist properties but at low doses analgesia is the
main property (Mitchell et al., 2009). Buprenorphine is often classified in the available literature
as a strong opioid, but due to the fact that it possesses only partial opioid receptor activating
properties and it has a ceiling effect,  it is included into the group of weak opioids in this thesis.
In  addition,  in  clinical  use,  bubrenorphine  is  often  prescribed  for  the  same  indications  as  the
other weak opioids, especially its transdermal formulation can be recommended for patients
experiencing pain of moderate intensity (step 2) (Gatti et al. 2010). Transdermal buprenorphine
may offer advantages over other weak opioids when used in older patients. It has been found to
be effective against chronic noncancer pain and because of its mainly biliary excretion into the
feces, there is no risk of accumulation even in cases of serious renal failure which is single most
important common organ deficit found in older people (Gianni et al., 2011). In addition,
transdermal buprenorphine has been well tolerated without evoking serious ADRs in older
patients (>70 years).
Strong opioids represent the third step in the WHO analgesic ladder (Figure 5). The opioids
of first choice in this group are morphine, oxycodone, hydromorphone and fentanyl (van Ojik et
al., 2012). Morphine is widely considered to be a first line strong opioid, but its toxic metabolites
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for those with high dose requirements or renal insufficiency may limit its usefulness.  The less
harmful choices are those opioids which do not form toxic metabolites and for whom the doses
can be adjusted in conditions of reduced hepatic or renal function. Oxycodone may be a better
oral opioid choice in older persons because of its high flexibility and tailoring possibilities
(Arnstein, 2010). It is almost totally metabolized in the liver and therefore active metabolites do
not accumulate in patients with renal failure (Mitchell et al., 2009). The oral bioavailability of
oxycodone is significantly higher than morphine and there is less interindividual variation.
Oxycodone is metabolised by the CYP2D6 enzyme and drugs that block that enzyme prolong
its effects by delaying its elimination (Davis and Srivastava, 2003). Even though oxycodone has
some favourable aspects, there are some pitfalls to be taken into account. Several case reports
have been published in recent years showing synergism of oxycodone with serotonergic agents
leading  the appearance of the serotonin syndrome (Rastogi et al., 2011).
Hydromorphone  and  fentanyl  are  typically  reserved  for  patients  with  severe  pain.
Hydromorphone is often administered in immediate release formulations whereas fentanyl is
most commonly administered as a long-acting transdermal patch applied to the skin (Arnstein,
2010). Fentanyl is a highly potent opioid and it has a rapid onset of action due to its lipophilic
properties (Davis and Srivastava, 2003). Long-acting transdermal fentanyl is indicated for
chronic pain only but it may be better tolerated in older people than oral morphine because it is
less constipating, produces less daytime drowsiness and less distruption of daily life, and can
be used for patients with renal or hepatic dysfunction (Arnstein, 2010, Davis and Srivastava,
2003). However, it should not be used in opioid naïve patients because fentanyl is 100 times
more  potent  than  morphine  and  the  fentanyl  transdermal  patch  is  an  inflexible  system;
furthermore, it may require several days to achieve steady-state drug level and subsequently
the drug can be released from skin deposits for as long as 24 hours after removal of the patch,
this time may even be extended in older patients since absorption is often delayed (Davis and
Srivastava, 2003). In Finland, the prevalence of transdermal fentanyl use seems to be higher
than that of morphine, oxycodone, and hydromorphone among older people (ǃ80 years) even
though the Finnish National Agency for Medicines has recommended that oral opioids should
be considered as the first-line treatment when a strong opioid is required to relieve severe pain
(Bell et al., 2009).
Table 2. Considerations and recommendations related to analgesics in the management of pain in older people. Data gathered from Abdulla, Adams et al. 2013, AGS
2009, Arnstein 2010, Davis, Srivastava 2003, Mitchell, Hilmer et al. 2009, O’Neil, Hanlon et al. 2012, Ong, Lirk et al. 2007 and Pergolizzi, Boger et al. 2008.
DRUG CONSIDERATIONS RECOMMENDATION
Paracetamol Renal and hepatic toxicity at doses > 4g in 24 h, at lower doses if
dehydration, malnutrition, alcohol abuse or renal or hepatic failure.
Efficacy varies in different pain conditions.
First-line analgesic drug, well-tolerated and relatively safe,
recommended daily dose, short-term use 4g/24h or continuous
use 3g/24h must not be exceeded. Efficacy should be checked.
NSAIDs,
Nonselective
Acetylsalicylic acid
Increased risk for GI-bleeding, renal failure, cardiovascular events
Plays a role in preventing cardiovascular diseases, but not in pain
management
Considered with caution, avoid if high GI-bleeding risk, renal or
heart failure, or concomitant drugs that increase GI toxicity.
Short-term use (<2 weeks) recommended. Concominant
gastroprotective agent can reduce the risk of upper GI-
bleedings. Topical products recommendable for localized pain.
Ibuprofen The lowest GI risk among nonselective NSAIDs, inhibits platelet effects
of low-dose ASA
Ibuprofen should not be used with low-dose ASA
Diclofenac, Naproxen Intermediate risk for GI bleeding when compared to ibuprofen,
diclofenac  carries a higher cardiovascular risk than naproxen
Naproxen recommended after ibuprofen
Ketoprofen,Ketorolac
   and Piroxicam
High GI risk Should be avoided due to high GI risk
Indomethacin Many fatal events involving older people, serious GI risk, CNS effects Indomethacin should not be used at all
NSAIDs,
COX-2 selective
Celecoxib
Etoricoxib
Lower GI risk, equal renal risk and elevated cardiovascular risk when
compared to nonselective NSAIDs
Metabolized mainly via CYP2C9, drug-drug interactions
Metabolized mainly via CYP3A4, drug-drug interactions
The smallest effective dose for the shortest duration should be
used to minimize the cardiovascular risk. Contraindicated in
ischemic heart disease, cerebrovascular disease or renal failure.
Considered with caution if CVD risk factors (hypertension,
hyperlipidemia, smoking, diabetes).
Weak opioids
Codeine
Tramadol
Buprenorphine
Prodrug, activated by CYP2D6, common side-effect: constipation
Prodrug, activated by CYP2D6, accumulates in renal impairment, may
cause confusion and seizures in older persons, drug-drug interactions
with serotonergic drugs
No accumulation in renal impairment, effective and well-tolerated
but as a partial agonist has a ceiling effect
Should be considered individually, codeine and tramadol
generally are not the best options for older patients. Codeine
should be avoided in renal failure and tramadol in hepatic
failure.
Buprenorphine is relatively safe in older patients, its half-life is
not changed in renal insufficiency.
Strong opioids
Morphine
Hydromorphone
Oxycodone
Fentanyl
Methadone
Sedation, confusion, hallucination, constipation, nausea
Relatively safe in hepatic failure but sensitive to renal function
Prolonged half-life in hepatic failure but can be used in renal failure
Almost exclusively metabolized by CYP2D6, accumulated significantly
in hepatic failure but relatively safe in renal failure
100 times more potent than morphine, transdermal fentanyl causes
less constipation than oral opioids
Long and variable half-life, prolonged effects in older people
Considered with caution, concurrent laxative recommended.
Lower doses are usually adequate due to decreased
clearance.Controlled-release formulations recommended.
Morphine and oxycodone are usually the first choices, but renal
and hepatic function must be considered before initiation.
Fentanyl should not be used for opioid initiation. Can be used
for patients with mild to moderate renal or hepatic dysfunction.
Methadone should be avoided due to unfavourable
pharmacokinetic properties and risk of accumulation.
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2.3.2 Nonpharmacological pain management
Nonpharmacological pain management includes variety of strategies that help pain patients by
releasing endogenous opioids, increasing blood flow in the treatment area, changing the mental
focus away from pain or improving functional capacity. Given the numerous complicating
factors (such as pharmacokinetic changes, multimorbidity, polypharmacy and susceptibility to
ADRs) associated with the pharmacotherapy of pain in older people, the importance of
nonpharmacological treatment should not be overlooked in the treatment of older patients with
chronic pain problems. Nonpharmacological pain management reduces the risk of
polypharmacy and ADRs. In addition, active nonpharmacologic self-management strategies to
reduce pain have been associated with lower levels of pain-related disability and reduced
health care use (Blyth et al., 2005). Therefore, nonpharmacologic therapies should be considered
not just as a complementary or alternative adjunct to medications, but as an indispensible
component  in  treating  older  patients  with  pain.  Older  people’s  willingness  to  try
nonpharmacological pain management approaches is often good i.e. more than two out of every
three chronic pain patients have reported a willingness to participate for non-pharmacological
therapies for managing pain (Austrian et al., 2005). The nonpharmacologic pain alleviating
methods include physical exercise, psychosocial interventions, body-based strategies,
relaxation, electrotherapy, cold or hot treatment and alternative medicine or strategies (Table 3).
Physical exercise is the most commonly used self-care method for pain management after
drug medication (Kemp et al., 2005, Turunen et al., 2004). More than 40% of older people (ǃ65
years) found that regular exercise was moderately or extremely helpful for their persistent pain
(Kemp et al., 2005). The improved strength in older adults had a positive effect on the
perception of pain and significantly diminished the quality of the pain after an eight-week
training period (Knutzen et al., 2007). Physical exercise, training and rehabilitation have an
important role in reducing pain related mobility limitation and participation restrictions in
older people (Thomas et al., 2004). It has also been reported that the functional decline among
older people can be minimized or delayed if the subjects take physical exercise. Since physical
exercise  is  an effective  intervention for  improving physical  functioning in  older  people  and it
can significantly improve pain management and pain related limitations, it should be
considered as a part of the care for all older individuals with chronic pain (American Geriatrics
Society 1998, Liu and Latham 2009).
Psychosocial interventions focus on the interactions between the mind, body and behavior
and they emphasize knowledge and self-management strategies. Cognitive behavioural
therapy, relaxation, hypnosis, visual imagery, meditation, and spirituality are examples of this
type of therapy (Bruckenthal, 2010). Cognitive behavioural therapy is a widely utilized method
for teaching chronic pain self-management and there are an increasing number of studies
confirming its utility for pain management in individuals aged 65 years or more (Keefe et al.,
2013, Nicholas et al., 2013). Its target is to alter pain-relevant thoughts, emotions and behaviours
during 6-12 sessions the subjects learn and practice pain-management skills (Keefe et al., 2013).
In the study of Nicholas, Asghari et al. (2013) cognitive behavioural therapy achieved a
clinically significant improvement on pain disability and on a short-term scale it was more
effective than exercises and usual care. Emotional disclosure, where the patients write or speak
for several 15–20 min sessions about their deepest thoughts and feelings related to a stressful
experience, may also have a role in pain management although the research results in the
literature are mixed (Keefe et al., 2013). Furthermore, there is a growing interest in the use of
mind-body interventions, such as mindfulness meditation and yoga with group discussions,
evidence that these approaches may be helpful and in fact preliminary research appears
promising. Mindfulness seems to increase well-being by improving sleep, attention skills as
well as emotional processing and the acceptance of pain (Morone et al., 2008). The mind-body
intervention may reduce mean pain scores even during a relatively short-term intervention
conducted over the Internet (Berman et al., 2009). However, it should be noted that these
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methods have been studied often with a small number of participants and therefore the
conclusions drawn may be questionable.
Manipulative and body-based strategies include chiropractic techniques, osteopathic
medicine, massage and acupuncture (Bruckenthal 2010). These strategies focus on body unity
issues, enhance homeostatic mechanisms and structure-function interrelationships that may
alleviate pain and discomfort for example in bones, joints and soft tissues. The use of
manipulative therapies is relatively common among the general population especially for back-
related pain problems, but there is little research concerning older populations (Ong et al., 2004,
Xue et al., 2008). Cold and warmth are common physical methods used to alleviate pain and
given the high benefit to risk ratio of such interventions and noting that each may lead to the
release  of  endogenous  opioids,  it  may  be  worth  while  consideringnthese  kinds  of
nonpharmacologic measures when appropriate. Dietary supplements such as vitamins, herbs,
fatty acids and probiotics comprise a mixed group of products that can be used to help in self-
management of pain. For example, correction of moderate vitamin D deficiency may be
beneficial in older people with knee or hip pain (Laslett et al., 2012). Glucosamine sulphate and
chondroitin sulphate are two of the most widely studied supplements and although there are
claims that they may of benefit in the treatment of osteoarthritis the evidence is controversial
(Bruckenthal, 2010, Wandel et al., 2010).
Unrelieved persistent pain often causes patients to seek relief from alternative practitioners
utilizing homeopathy, naturopathy, spiritual healing etc. Although there is little scientific
evidence for their efficacy, it is clear that alternative and complementary strategies are practiced
with  or  without  the  knowledge  of  the  treating  physician.  Nonetheless,  they  should  be
recognized as possible options for certain patients. The personal attention and physical contact
provided by practitioners of these alternative therapies may provide some degree of relief to
patients with persistent pain. However, many alternative interventions are costly and some
even may represent health risks (Smith and Dillon, 2009, Tovar and Petzel, 2009). Often the
physician is the only source of objective information on such options and for this reason, it
seems reasonable that clinicians should be aware of the growing field of alternative medicine
(especially in pain management).
Table 3. Examples of nonpharmacological pain management strategies. Gathered from Bruckenthal
2010; Kemp, Ersek et al. 2005; Shin and Kolanowski 2010 and Tsai, Liu et al. 2010.
NONPHARMACOLOGICAL PAIN MANAGEMENT STRATEGIES
Physical exercise Improving overall physical functioning, muscle strength and joint
mobility, physiotherapy, gym training, stretching, swimming
Psychosocial interventions Cognitive behavioural therapy, hypnosis, meditation, spirituality,
yoga
Rest and relaxation Sit/lie down, sleep, listen to music, read a magazine, watch TV,
avoid painful movements
Body-based strategies Massage, chiropractice, osteopathy, acupuncture
Electrotherapy Transcutaneous Electrical Nerve Stimulation (TENS)
Thermal stimulation Cold/hot pad or bath, warming ultrasound
Assistive device Walker, walking stick, joint support
Dietary supplements and
lifestyle
Vitamins, herbs, fatty acids, probiotics, glucosamine,
chondroitin, vegetarianism, losing weight
Alternative strategies Homeopathy, naturopathy, spiritual healing, energy healing,
aromatherapy
Education Arthritis self-management program, educational booklets
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2.4 SUMMARY OF THE LITERATURE
Pain is highly prevalent in community-dwelling older people with musculoskeletal pain in the
limbs being the most common type and site of pain. Both ageing and pain are very subjective
experiences and therefore recognizing and assessing pain and its effect on daily life in older
persons plays an important role in achieving appropriate management of pain and pain-related
problems. Older people and even healthcare professionals may view pain as an inevitable
consequence of aging but this “wear and tear” attitude can have devastating consequences. It
worsens overall  quality of life and may mean that older people limit their physical activity in
order to avoid further ‘wearing’ of painful limbs. The restriction of painful movements results
in atrophy of muscles which increases further the mobility limitation and additionally the fear
of pain accentuates the avoidance cycle. In the long run, this vicious circle increases pain and its
related functional restrictions. It seems that there is a complex mesh of factors influencing each
other and therefore it is extremely difficult to determine accurately which are the causes and
what are the consequences.
The early identification of people at high risk of pain-related mobility restriction and chronic
disability may allow preventive strategies, more intensive management, better use of resources,
all leading to a reduction in disability. It is important to combine both pharmacological and
nonpharmacological pain management strategies to achieve a multidimensional intervention to
help with an older person’s pain problems. However, there are significant challenges in this
kind of implementation and more research is needed to determine the most effective
interventions for older people. Although evidence about the effectiveness of improving pain
management and the prevention of the functional decline in older people is limited, it does
seem that more and more interest has arisen during the last decade. There are still many
research gaps that need to be filled in order to improve pain management in older people. For
example, little is known about the long-term pharmacokinetics, safety and efficacy of
commonly prescribed nonopioids and opioids, nor have the properties of specific medication
classes in older people been adequately compared. It is also important to identify those patient-
level and medication-level factors that influence the likelihood of experiencing positive or
negative treatment outcomes. Optimal nonpharmacological approaches combined with
pharmacological treatment should be examined and supplemented into pain management
guidelines. Furthermore, beliefs, attitudes and hopes of older pain patients and health care
professionals are important issues that need to be taken into account when developing new
interventions. There is a clear need to clarity the crucial factors that negatively impact on pain
management.
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3 Aims of the Study
The  overall  objective  of  this  study  was  to  investigate  pain,  analgesic  use  and  the  mobility
limitation associated with pain among community-dwelling older people (ǃ75 years) in Finland.
The specific aims of this study were:
1. To assess the prevalence and the pattern of analgesic use.
2. To investigate the relationship between pain, analgesic use and mobility limitation and
to identify factors associated with the mobility limitation.
3. To determine the persistence of musculoskeletal chronic pain and factors related to this
condition.
4. To clarity whether older persons with musculoskeletal chronic pain hope for more
attention to pain management from their physician and to investigate the persistence of
those hopes.
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4 Materials and Methods
4.1 GEMS STUDY
This thesis is based on the population-based GeMS study (Geriatric Multidisciplinary Strategy
for the Good Care of the Elderly). The GeMS is a multi-disciplinary health intervention study
that was conducted in the City of Kuopio, Eastern Finland, between 2004 and 2007. The study
was designed to evaluate the effects of annual Comprehensive Geriatric Assessment (CGA)
based interventions on health and nutritional status, functional capacity, drug use and
hospitalization in older persons.
4.1.1 Population
A random sample of 1000 persons aged ǃ75 years was drawn from the population register of
the City of Kuopio, Finland, on 1st November 2003 (88 253 inhabitants, 5615 aged ǃ75 years)
(Figure 7). These individuals were randomized into intervention (n=500) and control (n=500)
groups. Of those invited to participate to the study, 162 declined to attend, 55 died before the
examination and 2 moved to a different municipality. Thus, a total of 781 persons (78% of the
initial  sample,  404  in  the  intervention  group  and  377  in  the  control  group),  provided  written
consent to participate. The baseline examination was performed in 2004 and the study
continued with annual examinations conducted in 2005, 2006 and 2007. Of the study
participants at baseline, 233 (30%) were men and 548 (70%) women with a mean age 81.7 years
(range 75.3–99.0). The majority were community-dwelling (n=700) with 81 living in institutional
care. The attrition during the follow-up was mainly due to deaths. The details of the
populations examined in studies I–IV are presented in Table 4.
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Population
Inhabitants of Kuopio, n=88253, people aged  75 years,
n=5615
Random sample, n=1000
(1st November, 2003)
and randomization into two groups:
Intervention group, n=500 and Control group, n=500
2004, baseline examination, n=781
Intervention group# Control group
n=404  n=377
(CD*, n=361) (CD*, n=339)
Intervention
group:
17 died
77 refused
2 moved
Control
group:
38 died
85 refused
2005, examination, n=717
Intervention group# Control group
n=371  n=346
(CD*, n=331) (CD*, n=313)
2006, examination, n=657
Intervention group# Control group
n=339  n=318
(CD*, n=304) (CD*, n=284)
2007, examination, n=609
Intervention group Control group
n=315  n=294
(CD*, n=282) (CD*, n=258)
27 died
6 refused
25 died
5 refused
1 not reached
30 died
2 refused
25 died
2 refused
1 moved
24 died 22 died
2 refused
Figure 7. Flow chart of the GeMS study.
#) Intervention group underwent a CGA and multiple interventions
*) CD=Community-Dwelling
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Table 4. The community-dwelling participants in the studies included in this thesis.
STUDY POPULATION DESIGN MAIN OUTCOME
I All community-dwelling
participants in 2004, n=700
Observational
Cross-sectional
The use of analgesics
Additional data in the
thesis: Longitudinal
II All participants in 2004 fulfilling the
inclusion criteria, n=622
1) did not have moderate or severe
cognitive impairment
(MMSE score >18)
2) participated in the mobility
assessment
3) provided pain information
Observational
Cross-sectional
Mobility limitation
III Control group participants in 2005
fulfilling the inclusion criteria,
n=272
1) did not have cancer
2) did not have moderate or severe
cognitive impairment
(MMSE score >18)
3) did not drop out before follow-up
Observational
Cross-sectional and
longitudinal
The course of chronic
pain
IV All participants in 2005 fulfilling the
inclusion criteria below, n=270
1) did not have cancer
2) did not have moderate or severe
cognitive impairment
(MMSE score >18)
3) had chronic pain (3 months)
Observational
Cross-sectional and
longitudinal
A hope to receive
more attention to
pain management
4.1.2 Study protocol
The study protocol included an annual examination conducted in the years from 2004 to 2007
for all study participants. The participants were examined and interviewed annually by three
study  nurses,  who  were  committed  to  follow  written  guidelines  of  the  study.  During  the
examinations and interviews, information was collected on demographic characteristics, living
conditions, health status, functional capacity and drug use. The protocol also included some
laboratory tests in the years 2004 and 2006. All participants had normal access to primary and
specialized health care during the study period. In the GeMS study, several interventions were
performed, but in this thesis the purpose was not to investigate their impact, because pain and
pain medication was not on the focus of interventions.
Interventions
After the baseline examination, the participants in the intervention group underwent an annual
CGA that included a clinical examination, medication assessment and interventions to improve
nutritional status and functional capacity. The CGA was performed by a team of two physicians
(trainees in geriatrics), three study nurses, two physiotherapists and a nutritionist. One of the
original  physicians  left  the  study  after  the  first  baseline  assessments  and  was  replaced  by
another physician. The physician interviewed and examined the participants in the intervention
group  generally  within  two  weeks  after  the  nurse’s  interview.  The  physician  undertook  a
critical drug assessment and referred the patient to a specialist when necessary. Each
participant in the intervention group was supplied with a tailored training program (eg.
supervised muscle strength and balancing training once a week in the gym) compiled by a
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physiotherapist to improve functional capacity and mobility. Those who were at risk of
malnutrition (short Mini Nutritional Assessment score ǂ 11), received a nutritional intervention.
The nutritionist met the participant in the years 2005 and 2006, and spoked with the participants
at least every two months during the intervention helping participants with meal plans, dietary
issues etc. In addition, two experienced dentists performed an oral health assessment in the
participants in the intervention group and an oral intervention was carried out if needed.
4.1.3 Data collection
Annual interviews and examinations were performed in the municipal health centre or in the
participants’ current residence. The study nurses used a structured questionnaire during the
interview and when examining the participants. If the participant was unable to answer the
questions (e.g. due to dementia), a caregiver or home nursing staff responded instead. The data
collecting personnel had also access to medical records from the municipal health centre, home
nursing  service,  local  hospitals  and  Kuopio  University  Hospital  to  verify  the  accuracy  of
information collected during the interviews.
Participants were asked questions on living situation during the interview and they were
categorized as either community-dwelling (living in own home or in sheltered accommodation)
or under institutional care (nursing home, residential care home, long-term hospital care). They
were  also  asked  if  they  were  living  alone  or  with  some  other  person.  The  total  length  of
education was enquired and in  this  thesis  it  was  dichotomized into  two groups:  1)  6  years  or
less (compulsory primary education in Finland before the Second World War) and 2) more than
6 years (including additional and vocational education).
Pain and the use of analgesics
Annual interviews and examinations included the assessment of pain containing structured
questions about the presence, location, frequency and severity of pain. Eighteen community-
dwelling participants (2.5%) did not provide any information about the presence of pain at
baseline in 2004. The study nurses interviewed the participants with regard to their
prescriptions and OTC drug use. To reduce the possibility of recall error, the participants were
asked to bring along their prescription forms and medication packages to the interview.
Definitions of pain and analgesic drugs are described in more detail in chapter 4.2.
Mobility
The mobility of the participants was assessed with Timed Up and Go test (TUG) (study II).  In
the  TUG,  the  participant  rises  from a  standard chair  with  armrests,  using arms for  support  if
needed, walks three meters as quickly as possible, turns around and walks back to return to a
fully seated position in the same chair. During the test, the participants wore their regular
footwear and were allowed to use any mobility aids that they would normally require. The time
taken to complete the test was measured with a stopwatch and participants were considered to
have a mobility limitation if the time exceeded 13.5 seconds or if they were unable to perform
the test. The cut-off point was based on the study of Shumway-Cook et al. (2000), in which the
longer times were associated with an increased risk of falling among people aged 65–95 years.
In addition, self-rated mobility was asked by the question: “Are you able to walk 400
meters?” (studies I, III and IV). Participants chose one option from four alternatives: 1) yes,
without difficulties 2) with difficulties, but independently 3) not without the help of some other
person 4) no. In the study I groups 3–4 were combined into group “not independently”. In
studies III and IV groups 2–4 were considered to have mobility difficulties and they were
compared to the subjects in group 1
Health and functional characteristics
Participants’ body weight and height were measured and the Body Mass Index (BMI) calculated
to reveal obesity. Information of chronic diseases was collected from the Finnish Social
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Insurance Institution (SII) Special Reimbursement Register, interviews, medical records and lab
tests. The question evaluating self-rated health included 5 response options and the
subcategories 1–2 (good and fairly good) and 4–5 (fairly poor and poor) were combined in the
analyses conducted in study I. The middle category 3 (moderate) was combined with categories
1–2 in study II and with categories 4–5 in studies III-IV to create a two class variable.
During the interviews, Mini Mental State Examination (MMSE) (Folstein et al., 1975) was
performed to define the participants’ cognitive performance and the 15-item Geriatric
Depression Scale (GDS-15) (Sheikh and Yesavage, 1986) to assess depressive symptoms. In
addition to mobility tests, functional status of the participants was determined with
Instrumental Activities of Daily Living score (IADL) (Lawton and Brody, 1969), Barthel index
(Mahoney and Barthel, 1965), muscle strength and self-reported physical activity. Detailed
definitions concerning health and functional characteristics are presented in chapter 4.2.
4.1.4 Ethical issues
The GeMS study protocol was approved by the Research Ethics Committee of the Hospital
District of Northern Savo as required by Finnish legislation. All the participants were informed
about the study and they or their caregivers signed a written informed consent form.
4.1.5 Data management and statistical analyses
All the data collected in the GeMS study were entered into the SPSS statistical software for
Windows (SPSS Inc., Chicago, USA) and all the statistical tests and analyses were performed
with this software. In the analyses different versions of the software were used (I–II: 15.0, III:
17.0 and 19.0, IV: 19.0). In addition, Microsoft Exel 2007 was used to create bar graphs (I and II).
The characteristics of participants at baseline were compared using Pearson’s Λ2-test for
categorical variables and Mann-Whitney U-test for continuous variables. Logistic regression
models were used to determine Odds Ratios and 95% Confidence Intervals. P-values <0.05 were
considered statistically significant.
4.2 DEFINITIONS
4.2.1 Pain
Musculoskeletal pain was defined as pain experienced in the shoulders, neck, back, hips, knees,
or other sites in the upper or lower body. Headache and persistent pain with symptoms
resembling “electric shocks, pressure-evoked pain, numbness, stabbing or tingling” (suggestive
of neuropathic pain) were also asked. The frequency of pain was assessed with the question
“For how long have you had pain?” and three response options were given: less than 1 month,
1–3 months, more than 3 months. Pain was defined as chronic, if pain duration was more than 3
months. The severity of pain was assessed with a 10-point Numeric Rating Scale (NRS), which
had the numbers 1–10 written from left to right; the participant cirkled the number that
corresponded best to his/her pain. Pain rated with numbers 2–4 was categorized as mild and
pain rated with numbers 5–10 as moderate to severe. Unfortunately, due to a misunderstanding
in the data collecting process, the pain data from the control group was incomplete at the
baseline in year 2004. Detailed pain definitions in the studies included in this thesis are
presented in Table 5.
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Table 5. The definitions of pain in the studies I–IV.
STUDY PAIN DEFINITION
I Any pain
Any pain during the previous month, e.g. pain in the shoulders, neck, back, hips,
knees, or other sites in the upper or lower body. Headache and persistent pain with
symptoms resembling “electric shocks, pressure-evoked pain, numbness, stabbing or
tingling” (suggestive of neuropathic pain) were also included.
II Musculoskeletal pain
Pain experienced in the shoulders, neck, back, hips, knees or other sites in the upper
or lower body for at least 7 days during the month immediately preceding the
assessment.
III–IV Chronic musculoskeletal pain
Pain experienced in the shoulders, neck, back, hips, knees or other sites in the upper
or lower body for at least 3 months immediately preceding the assessment.
4.2.2 Analgesic drugs
Analgesic drugs were categorized into four groups according to the Anatomical Therapeutic
Classification System recommended by the World Health Organization (WHO, 2014). Detailed
analgesic groups and subgroups are presented in Table 6. Low-dose asetylsalicylic acid (ǂ250mg
daily) was excluded i.e. it was being used as an antithrombotic agent. Acetylsalicylic acid, with
caffeine and vitamin C powder (marketed for flu) and orphenadrine in combination with
paracetamol (marketed as a muscle relaxant) were excluded from the list of analgesic drugs.
Analgesic use was classified as either daily or as needed (less frequent than daily). Those
participants who were analgesic users at the time of all four annual interviews were defined as
frequent users.
Table 6. The classification of analgesic drugs. The table includes only drugs available on the market
in 2004–2007.
ANALGESIC GROUP ATC-CODE CHEMICAL NAMES
Paracetamol N02BE01 Paracetamol (acetaminophen)
NSAIDs
   Traditional
   COX-2 selective
N02BA01
M01AB
M01AC
M01AE
M01AG
M01AX01
M01AH
Acetylsalicylic acid
Indomethacin, diclofenac, etodolac, ketorolac
Piroxicam, tenoxicam, meloxicam
Ibuprofen, naproxen, ketoprofen, tiaprofenic acic,
dexibuprofen, dexketoprofen
Mefenamic acid, tolfenamic acid
Nabumetone
Celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib,
lumiracoxib
Opioids
   Mild
   Strong
N02AA59
N02AE01
N02AX02
N02AA
N02AB03
Codeine
Buprenorphine
Tramadol
Morphine, hydromorphone, oxycodone
Fentanyl
Topical analgesics M02AA
M02AC
Piroxicam, ketoprofen, diclofenac
Preparations with salicylic acid derivatives
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4.2.3 Health and functional characteristics
Definitions of the factors indicating the health and functioning of the participants are compiled
in  Table  7.  Comorbid  conditions  influencing  physical  function  were  determined  with  the
modified version of Functional Comorbidity Index (FCI) (Groll et al., 2005). The modified FCI
was calculated by a simple sum score of 13 diseases found in the data of GeMS study: 1)
rheumatoid arthritis and other connective tissue diseases, 2) osteoporosis, 3) asthma or chronic
obstructive pulmonary disease (COPD), 4) coronary artery disease, 5) heart failure, 6)
myocardial infarction, 7) multiple sclerosis or Parkinson’s disease, 8) stroke, 9) diabetes type I or
II, 10)  depression, 11) visual impairment, 12) hearing impairment and 13) obesity (BMI < 30.0).
Patient diagnoses were obtained from registers maintained by the Social Insurance
Institution (SII)  of  Finland,  self-report  and medical  records.  Finnish National  Prescription and
Special Reimbursement Registers maintained by the SII were used to screen for the presence of
rheumatoid arthritis and other inflammatory connective tissue diseases (the data did not
include  osteoarthritis),  chronic  asthma  or  COPD,  Parkinson’s  disease,  or  multiple  sclerosis.
Other conditions of the FCI were ascertained either from participant self-report or the medical
records. Depressive symptoms were assessed with the GDS-15 (scores of 5 or more were
considered as being indicative of depression) or any of the depression types defined by DSM-IV
criteria (major depression, dysthymia, other depression, or depression episode of bipolar
disease). The presence of each of the 13 conditions listed previously included in the FCI resulted
in a score of one and thus a higher FCI sum score represented greater comorbidity.
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Table 7. Definitions of the health and functional characteristics of the study participants.
FACTOR DEFINITION
S
TA
TE
O
F
H
EA
LT
H
BMI The Body Mass Index: body weight (kg) divided by body height
squared in meters, score 30 indicating obesity.
FCI
(scale 0–13)
The modified Functional Comorbidity Index (Groll et al., 2005)
revealing the participants’ comorbid conditions with a sum score of 13
diseases (detailed description in the text).
GDS-15
(scale 0–15)
The 15-item Geriatric Depression Scale to screen for depressive
symptoms (Sheikh and Yesavage, 1986), score 5 indicating
depressive mood.
MMSE
(scale 0–30)
The Mini Mental State Examination scale to screen for cognitive
performance (Folstein et al., 1975), score <18 indicating moderate to
severe cognitive impairment.
Self-rated
health
Subjective health assessed by the question “How would you describe
your present health?” with five options: 1) good 2) fairly good 3)
moderate 4) fairly poor 5) poor. (Cousins, 1997)
Diseases
Arthritis Included rheumatoid and osteoarthritis. Rheumatoid arthritis was
confirmed from the SII Special Reimbursement Register. Assessment
of osteoarthritis was based on the baseline clinical examination and
medical records.
Asthma/COPD Based on the SII Special Reimbursement Register code indicative of
chronic asthma or COPD.
CVD Cardiovascular disease included coronary artery disease, heart failure
and myocardial infarction. The presence of CVD was based on the SII
Special Reimbursement Register codes (studies I–II) and the
information was complemented from the interview and medical
records (studies III–IV).
Diabetes Included types I and II. The presence of diabetes was based on the
SII Special Reimbursement Register codes (Studies I–II) and the
information was complemented from the interview, medical records
and lab tests (studies III–IV).
Stroke Included verified (from medical records) brain infarction due to
thromboembolism, ICH, subarachnoidal bleeding or unclassified
reason.
FU
N
C
TI
O
N
A
L
S
T
A
T
U
S
IADL
(scale 0–8)
The Instrumental Activities of Daily Living scale (Lawton and Brody,
1969) estimating functional capacity, score <6 indicating reduced
daily function.
Barthel Index
(scale 0–100)
Standardized tool for measuring functional status (Mahoney and
Barthel, 1965), score <80 indicating reduced independence.
Muscle strength Maximal isometric knee extension strength in a sitting position using
an adjustable dynamometer chair (Good Strength, Metitur Oy,
Palokka Finland). The results were categorized and divided by age
and sex into tertiles. The highest tertile was compared to the lower
tertiles.
Physical
activity
Assessed with a modified version of the scale of Grimby (Grimby,
1986). Categorization on the basis of self-reported physical activity
into a sedentary group (no exercise, or at most light walking 1–2
times a week) and more active group.
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5 Results
5.1 THE BASELINE CHARACTERISTICS OF THE STUDY PARTICIPANTS
The age of the community-dwelling participans’ (n=700) ranged from 75.3 to 99.0 years with
mean age of 81.3 ± 4.6 years. The majority of participants were women (n=486, 69.4%) (Table 8).
The most common medical conditions suffered by the participants were cardiovascular diseases
(n=455, 65.0%) and arthritis (n=278, 39.7%). Almost half of the participants (n=318, 45.4%) were
users of daily or as-needed analgesics.
Slightly over half (51.7%, n=362) of the participants were without any pain but almost as
many did have pain (45.7%, n=320). Those participants experiencing pain were more often
women, had depressive symptoms, diabetes and a sedentary lifestyle (Tables 8 and 9). High
BMI, arthritis, mobility limitation, poor self-rated health and daily use of analgesics were
significantly more common among participants with pain than in those without pain. In
addition, they were taking a higher total number of drugs (excluding analgesics) and had a
higher FCI score.
Analgesic users were more often female and living alone than analgesic non-users,
irrespective of the presence of pain (p<0.05). Users experiencing any pain had depressive
symptoms, poor self-rated health, asthma/COPD, diabetes, arthritis and daily analgesics more
commonly than those without pain. Painfree analgesic users had lower functional statuses than
their painfree non-user counterparts. In participants with any pain, the analgesic users had
more often depressive symptoms and rated their health as poorer than non-users.  In addition,
they had more commonly cardiovascular disease, arthritis, a low IADL score and mobility
limitations.
Table 8. The baseline (2004) Characteristics of the community-dwelling participants (n=700) according to the precence of any pain and the use of
analgesics.
Variable (n=missing) Without any painn=362
With any pain
n=320
No pain data,
n=18
Number of
missings
Non-user, n (%)
273 (75.4)
User, n (%)
89 (24.6)
Non-user, n (%)
98 (30.6)
User, n (%)
222 (69.4)
Age, 75–79
        80–84
        85
149 (54.6)
82 (30.0)
42 (15.4)
41 (46.1)
29 (32.6)
19 (21.3)
50 (51.0)
32 (32.7)
16 (16.3)
98 (44.1)
70 (31.5)
54 (24.3)
8
2
8
Sex, female 166 (60.8) 69 (77.5) 65 (66.3) 177 (79.7) 9
Education, 0–6 years 18 121 (45.7) 45 (51.7) 46 (47.4) 118 (54.9) 12
Living alone 138 (50.5) 63 (70.8) 48 (49.0) 143 (64.4) 10
Depressive symptoms,
    GDS-15 score 5–15 11 17 (6.3) 4 (4.5) 5 (5.3) 28 (12.9) 0
MMSE score 0–24 1 62 (22.8) 26 (29.2) 21 (21.4) 56 (25.2) 9
BMI  30 10 38 (14.0) 17 (19.8) 23 (24.0) 65 (29.3) 3
Poor self-rated health 2 132 (48.4) 43 (48.3) 52 (53.1) 163 (73.4) 7
FCI score, mean±SD 2.1±1.6 2.93±1.7
2.0±1.5 2.2±1.7 2.5±1.7 3.1±1.7
Asthma/COPD 26 (9.5) 3 (3.4) 10 (10.2) 27 (12.2) 0
Cardiovascular disease 166 (60.8) 61 (68.5) 58 (59.2) 158 (71.2) 12
Diabetes 4 38 (14.0) 10 (11.2) 15 (15.3) 49 (22.2) 2
Stroke 9 35 (13.0) 11 (12.5) 10 (10.3) 36 (16.4) 2
Arthritis 34 61 (23.4) 34 (41.5) 46 (48.9) 134 (62.9) 1
Number of drugs, mean±SD 5.4±3.4 7.7±4.0
5.0±3.2 6.9±3.4 5.5±3.1 8.7±3.9
Use of analgesics,
    As needed
    Daily
-
-
75 (84.3)
14 (15.7)
-
-
163 (73.4)
59 (26.6)
6
1
Functional status
IADL score 0–6 2 93 (34.1) 32 (36.4) 23 (23.5) 91 (41.2) 13
Barthel index 0–80 5 10 (3.7) 12 (13.5) 4  (4.1) 23 (10.4) 2
Self-rated mobility, not able to
      walk 400m without help 22 (8.1) 15 (16.9) 5 (5.1) 35 (15.8) 2
Sedentary 50 81 (31.0) 36 (44.4) 36 (38.3) 102 (48.1) missing data
Poor muscle strength 48 116 (44.4) 35 (42.7) 39 (41.5) 108 (50.7) missing data
Mobility limitation, TUG > 13,5s 78 57 (22.4) 25 (33.8) 24 (26.1) 93 (46.3) missing data
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Table 9. Significant differences (p<0.05) between participants with or without pain and users or
non-users of analgesic drugs as assessed with chi-square test.
with pain vs.
without pain
painfree users
vs. non-users
painful users
vs. non-users
users with pain
vs. without pain
Sex, female 0.002 0.004 0.010
Living alone 0.001 0.009
Depressive symptoms 0.023 0.043 0.029
BMI  30 <0.001
Poor self-rated health <0.001 <0.001 <0.001
Asthma/COPD 0.018
Cardiovascular disease 0.035
Diabetes 0.018 0.026
Arthritis <0.001 0.001 0.022 0.001
Daily use of analgesics <0.001 0.041
IADL score 0–6 0.002
Barthel index 0–80 0.001
Not able to walk 400m
without help 0.017 0.008
Sedentary 0.005 0.026
Mobility limitation (TUG) <0.001 0.047 0.001
FCI score <0.001 <0.001 <0.001
Total number of drugs <0.001 <0.001 <0.001 <0.001
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5.2 THE PREVALENCE AND LONGITUDINAL COURSE OF ANALGESIC USE
The prevalence of analgesic use among community-dwelling people aged ǃ75 years (n=700) was
45.4% (n=318) in 2004 (Study I). The use of analgesics according to gender and age group is
presented in Figure 8. The prevalence of analgesic use on a daily or on an as needed basis was
higher among female participants (females, 51.5%; males, 31.7%; p<0.001) and in those in the
older age groups (aged 75 to 79, 41.3%; 80 to 84, 46.5%; over 85, 54.0%; p<0.05).
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Figure 8. The prevalence (%) of daily and as needed analgesic use in 2004 according to sex and age
group (n=700).
The longitudinal course of analgesic use in the control and in the intervention group in 2004–
2007 is shown in the Table 10. The overall prevalence of analgesic use increased from 45.4% to
54.9% during the study years. Of all analgesic users at baseline (n=318), 52.2% (n=166) reported
use in all three follow-up years and only 16.7% (n=53) had discontinued the use of analgesics
during the follow-up period. Conversely, those participants who were analgesic nonusers at
baseline (n=382), only 42.1% (n=161) remained as nonusers also over the next three years
whereas 31.4% (n=120) had started to use analgesics on a daily or on an as needed basis. In
addition, 11.6% (n=37) of baseline users and 11.5% (n=44) of baseline nonusers fluctuated
between user and nonuser status. The loss due to deaths (n=100), refusals (n=18) and contact
problems (n=1) was 19.5% (n=62) among the baseline analgesic users compared to 14.9% (n=57)
among the baseline nonusers.
If the study groups are considered separately, the overall prevalence of analgesic use
increased by 15% in the control group whereas the increase was only 10% in the intervention
group during the  study years.  The proportion of  frequent  users  and nonusers  was almost  the
same in both groups. There were slightly more new incident cases and discontinuous cases in
the intervention group, but the differences were not statistically significant (p=0,22; p=0,18).
Fluctuating between user and nonuser status was twice as common in the control group as in
the intervention group (p=0.008). The attrition due to deaths, refusals and other reasons did not
differ in statistical terms between the groups (p=0.50).
75-79 years 80-84 years 85+ years
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Table 10. Use of analgesics among community-dwelling GeMS-study participants in control and
intervention groups in 2004–2007.
ALL
2004 (n=700)
Users 46%, n=318
2005 (n=656)
Users 51%, n=335
2006 (n=621)
Users 55%, n=340
2007 (n=581)
Users 55%, n=319
C
O
N
T
R
O
L
G
R
O
U
P
n
=
33
9
at
ba
se
lin
e
User, n=159
(7 died, 2 refused
before next examination)
User, n=124
(11 died, 2 refused)
User, n= 94
(5 died, 1 refused)
User, n=79
Non-user, n=9
Non-user, n=17
(3 died)
User, n=8
Non-user, n=6
Non-user, n=26
(1 died)
User, n=11 User, n=8
Non-user, n=3
Non-user, n=14 User, n=8
Non-user, n=6
Non-user, n=180
(6 died, 3 refused,
1 could not be contacted
before next examination)
User, n=41
(1 died)
User, n=32
(3 died)
User, n=19
Non-user, n=10
Non-user, n=8 User, n=2
Non-user, n=6
Non-User, n=129
(6 died, 1 moved)
User, n=27
(3 died, 1 refused)
User, n=15
Non-user, n=8
Non-user, n=95
(4 died)
User, n=18
Non-user, n=73
Users 41% (159/339) Users 52% (165/320) Users 55% (164/298) Users 56% (157/278)
IN
T
ER
V
EN
T
IO
N
G
R
O
U
P
n
=
36
1
at
ba
se
lin
e
User, n=159
(9 died, 2 refused
before next examination)
User, n=127
(4 died, 1 refused)
User, n=111
(9 died)
User, n=87
Non-user, n= 15
Non-user, n=11
(1 died)
User, n=2
Non-user, n=8
Non-user, n=21
(2 died)
User, n=5
(1 died)
User, n=1
Non-user, n=3
Non-user, n=14
(1 died)
User, n=4
Non-user, n=9
Non-user, n=202
(10 died, 4 refused
before next examination)
User, n=43
(3 died, 1 refused)
User, n=31
(2 died)
User, n=25
Non-user, n=4
Non-user, n=8 User, n=0Non-user, n=8
Non-user, n=145
(2 died)
User, n=29
(4 died)
User, n=19
Non-user, n=6
Non-user, n=114
(2 died)
User, n=24
Non-user, n=88
Users 44% (159/361) Users 51% (170/336) Users 54% (176/323) Users 53% (162/303)
SUMMARY All participants
n=700
%(n)
Control group
n=339
%(n)
Intervention group
n=361
%(n)
Frequent users 24% (166) 23% (79) 24% (87)
Non-users 23% (161) 22% (73) 24% (88)
New incident cases 17% (120) 15% (52) 19% (68)
Discontinuous cases 8% (53) 6% (21) 9% (32)
Fluctuating cases 11% (81) 16% (53) 8% (28)
Deaths 14% (100) 15% (50) 14% (50)
Lost to follow up 3% (19) 3% (11) 2% (8)
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5.3 PAIN AND THE USE OF ANALGESICS IN RELATION TO MOBILITY
LIMITATION
Of the 622 participants in study II (Table 4), 199 (32.0%) had some degree of mobility limitation
as estimated in the TUG test. Forty percent (n=251) reported musculoskeletal pain and 61.8%
(n=155) of them rated their pain as either severe or moderate. In addition, in this group of
participants 44.2% (n=275) were daily (n=58) or as needed (n=217) analgesic users. The
percentage of mobility limitation was higher in the persons who also reported musculoskeletal
pain (43.8%, n=110) in comparison to those without musculoskeletal pain (24.0%, n=89) and also
in analgesic users (42.9%, n=118) as compared analgesic nonusers (23.3%, n=81).
The mobility limitation was most common among participants with pain using paracetamol
only (72.2%, n=39), followed by users of opioids in combination with other drugs, (52.9%, n=27)
(Figure  9).  In  the  participants  without  musculoskeletal  pain,  a  mobility  limitation  was  most
prevalent among users of paracetamol only (44.4%, n=4) and paracetamol with NSAIDs (43.5%,
n=4), but due to the small number of cases, these results should be considered with caution.
The results concerning the factors associated with mobility limitation in older persons having
musculoskeletal pain and using analgesic drugs are presented in Table 11.  In the unadjusted
regression model, participants with higher age, female sex and living alone exhibited a 2–3
times higher risk for mobility limitation than younger and male participants or those living
with somebody. In addition, poor self-rated health, cardiovascular disease, depressive
symptoms, poor muscle strength and sedentary lifestyle were associated with a mobility
limitation in the unadjusted model.
After adjustments for age, sex, BMI, living alone, self-rated health, cardiovascular disease,
chronic pulmonary disease, diabetes, depression, arthritis, physical activity and muscle
strength, the association between mobility limitation and higher age, living alone, poor self-
rated health, sedentary lifestyle and poor muscle strength was somewhat attenuated but
nonetheless remained statistically significant. The association between mobility limitation and
female sex, cardiovascular disease and depressive mood was not statistically significant in the
adjusted regression model.
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Figure 9. The percentage of participants with mobility limitation (TUG <13.5s) in those subjects
with musculoskeletal pain (n=251) subdivided according to their use of analgesics.
Table 11. Sociodemographic and health characteristics associated with mobility limitation among analgesic users with musculoskeletal pain.
Analgesic users with musculoskeletal pain
n=177
Variable Mobility limitation Unadjusted
OR (CI 95%)†
Adjusted
OR (CI 95%)†§No (n= 87) Yes (n=90)
n % n %
Age, y 80 29 33.3 58 64.4 3.63 (1.95-6.74) 2.54 (1.18-5.50)
Sex Female 65 74.7 78 86.7 2.20 (1.01-4.78) 1.73 (0.64-4.66)
Body Mass Index 30 26 29.9 29 32.2 1.12 (0.59-2.11) 0.61 (0.26-1.45)
Living alone Yes 44 50.6 68 75.6 3.02 (1.60-5.72) 2.37 (1.03-5.47)
Self-rated Health Poor 8 9.2 36 40.0 6.58 (2.84-15.26) 6.40 (2.16-18.96)
Concominant disease
Depressive symptoms
Cardiovascular 59 67.8 74 82.2 2.20 (1.09-4.43) 2.40 (0.97-5.91)
Asthma/COPD 9 10.3 15 16.7 1.73 (0.72-4.20) 1.40 (0.47-4.15)
Diabetes 15 17.2 23 25.6 1.65 (0.79-3.42) 1.87 (0.71-4.96)
Arthritis 60 69.0 61 67.8 0.95 (0.50-1.78) 0.74 (0.33-1.66)
GDS-15 5 7 8.0 20 22.2 3.27 (1.30-8.18) 0.79 (0.24-2.59)
Physical activity Sedentary 28 32.2 61 67.8 4.43 (2.36-8.33) 2.77 (1.28-6.02)
Muscle strength Poor 25 28.7 60 66.7 4.96 (2.62-9.39) 3.45 (1.53-7.81)
Want more attention to pain Yes 37 42.5 46 51.1 1.41 (0.78-2.56) 1.53 (0.70-3.37)
** p < 0.001, * p < 0.05
†OR=Odds Ratio; 95% CI=95% Confidence Interval
§Adjusted for age, sex, BMI, living alone, SRH, CVD, COPD, diabetes, depression, arthritis, physical activity and muscle strength
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5.4 PERSISTENCE OF CHRONIC PAIN
Of the 272 participants examined in study III (Table 4), in 2005 almost half (48.9%, n=133)
reported nonmalignant chronic pain at baseline. After the two follow-up years, 99 were
persistent cases reporting chronic pain every year, 45 were incident cases starting to report
chronic  pain  and  36  were  discontinuous  cases  ceasing  to  experience  chronic  pain  during  the
follow-up.  The  no  chronic  pain  group  consisted  of  those  participants,  who  did  not  report
chronic pain in any of the study years.
The use  of  analgesic  drugs  was most  common in  the  persistent  chronic  pain group (Figure
10). During the study years 2005–2007, the prevalence of analgesic use increased in persistent
and  incident  chronic  pain  groups,  fluctuated  in  the  discontinuous  chronic  pain  group  but  it
remained almost the same in no chronic pain group. Most participants with persistent chronic
pain rated their pain either as moderate or severe in all of the study years, although the
percentage of moderate or severe pain decreased slightly (Figure 11).
Figure 10. Percentages of daily and as needed analgesic use in 2005-2007 in participants with
persistent, incident or discontinuous chronic pain and in participants not having chronic pain during
the study period.
3
18
10
10
16
17
13
24
20
21
41
46
33
65
59
60
0 20 40 60 80 100
2007
2006
2005
2007
2006
2005
2007
2006
2005
%
Daily As needed
Persistent
chronic pain
n=99
Incident
chronic pain
n=45
Discontinuous
chronic pain
n=36
41
Figure 11. Percentages of dichotomized pain intensity according to chronic pain group in 2005-2007
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5.5 HOPE FOR MORE ATTENTION TO BE PAID TO PAIN MANAGEMENT
At baseline in 2005, 41% of community-dwelling participants who experienced chronic
musculoskeletal pain were hoping that the physician would be paying more attention to the
management of their pain. This hope was most common among women (41.9%, n=85 vs. men
37.3%, n=25) and in the youngest age group (76–79 years 47.5%, n=47; 80–84 years 36.6%, n=37;
ǃ85 years 37.1%, n=26). At baseline, half (n=49) of those with persistent chronic pain (n=99) in
the study III hoped that the physician would be paying more attention to their pain
management. However, this hope, as well as the pain intensity decreased during the next two
years (Figure 12). In addition, the use of analgesics increased from 73.7% to 81.8% during the
study period.
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Figure 12. The percentages of pain intensity, analgesic use and the hope for more attention to be
paid to pain management during years 2005-2007 in participants with persistent chronic pain
(n=99).
43
6 Discussion
6.1 DISCUSSION OF THE RESULTS
This study revealed that almost half of the community-dwelling older participants were
experiencing musculoskeletal chronic pain at baseline and it was higly persistent in its nature.
The use of analgesics was common especially among women, and analgesics were most
commonly used on an as needed basis. In addition, both the musculoskeletal pain and the use
of analgesics were associated with mobility limitations. An important finding was that 40% of
those with chronic musculoskeletal pain expressed a hope that the physician would be paying
more attention to the pain management, i.e. clear evidence of a need for better pain
management.
6.1.1 Pattern of analgesic use
This study showed that almost half of the community-dwelling older participants were
analgesic users, most commonly analgesic drugs were being taken on an as needed rather than
on a daily basis. The prevalence of daily analgesic use among all study participants was almost
similar to that described in a previous Finnish study, conducted in 1998 in the same
municipality with same sampling strategy (Hartikainen et al., 2005). There are some possible
reasons why the daily use was relatively low, even in those individuals experiencing pain. It
may be that the people only experienced mild pain or that they had either experienced or were
at least concerned about the posible ADEs associated with daily use. The proportion of
analgesic users that were taking analgesics on a daily basis was slightly higher in 2004 than
1998. This difference results from a lower overall analgesic use in the present study. Another
Finnish  study  revealed  a  higher  prevalence  of  regular  analgesic  use  in  1999,  but  it  should  be
noted that regular use was defined as weekly not daily use as was conducted in the present
study (Pitkälä et al., 2002). In a recent study, every second older (aged >74 years) person with
symptomatic radiographic knee osteoarthritis was a frequent user (i.e. on more than half of the
days in the month prior to the assessment) of prescription or OTC analgesics (Kingsbury et al.,
2013). The results of the present study may point to inadequate pharmacological treatment of
pain in community-dwelling older persons because one third of those experiencing pain were
nonetheless nonusers of analgesics. The reasons may include poor communication with health
care providers, hesitance to take medicines for three possible reasons, fear of addiction, adverse
side-effects or drug-drug interactions as well as the common belief that pain is a normal part of
aging (Cornally and McCarthy, 2011, Davis et al., 2002).
In the present study the prevalence of analgesic use on a daily or an as needed basis doubled
from those in the youngest age group to oldest age group. There were gender-related
differences, i.e. the prevalence increased significantly among women with age whereas it
remained almost the same or even decreased slightly among men. This is in line with the
studies of Blyth, March et al. (2001) and Kingsbury, Hensor et al. (2013) although their
investigations included a relatively small number of older individuals aged 75 or more. The
finding that the overall and daily use of analgesics was more common among women than men
was expected because according to most reports, pain is more prevalent and widespread in
women than men (Blyth et al., 2001, Jakobsson, 2010, Leveille et al., 2005, Thomas et al., 2004). In
addition, older women may be more willing to report pain and seek help than men (Greenspan,
Traub 2013). The result is consistent with previous studies demonstrating the higher prevalence
of analgesic use in older women in comparison to similar aged men (Kingsbury et al., 2013,
Paulose-Ram et al., 2003, Sadowski et al., 2009). Living alone was more common among the
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analgesic users than nonusers; this same trend was found by Sawyer, Bodner et al. (2006) who
reported that an unmarried status was associated with prescription analgesic use.
This study revealed also the results of longitudinal course of analgesic use among
community-dwelling older people. The overall prevalence of analgesic use increased almost
10% between years 2004–2007. The increase was similar in the intervention and control groups
and therefore the medication interventions concerning persons in intervention group did not
account for this in ceased analgesic use. In a longitudinal setting, the frequent use of analgesics
was more common than that of being a stable nonuser status during the 4-year study period.
However, we did not analyse the medication types used by individuals and whether they
discontinued the use of certain analgesic and changed some alternative. The initiation of
analgesic use was almost twice as common as the discontinuation of the analgesic use. There
might have been higher pain levels that have increased the use of analgesics, but unfortunately
it was not possible to determine the intensity of pain in relation to analgesic use in this study
setting.
The present finding that paracetamol was the most commonly used analgesic drug among
older people, was encouraging in the light of guidelines, where paracetamol is recommended as
the step 1 analgesic drug in the treatment of pain (WHO, 1996) and it is recognized as the first
line treatment for older people (Abdulla et al., 2013, American Geriatrics Society, 2009). In the
previous Finnish study (Hartikainen et al., 2005), conducted in 1998 in the same municipality
with a similar sampling strategy, NSAIDs were more frequently used among Finns aged ǃ75
years  and  thus  the  present  result  reflects  a  shift  away  from  their  use.  This  change  may  have
been promoted by Finnish care guidelines that have warned about ADRs, such as the high risk
of gastrointestinal and renal toxicity associated with NSAIDs (Non-Steroidal Anti-inflammatory
Drugs: Current Care Summary, 2009).
The use of opioids, especially strong opioids, was low in the present study, although during
the last decade the use of strong opioids has increased rapidly in Europe and North America
(Bell et al., 2009, Garcia del Pozo et al., 2008, Hamunen et al., 2008, Thielke et al., 2010). Some
infrequent opioid use has been found previously in older people with osteoarthritis (Kingsbury
et al., 2013). Opioids are often reserved for patients with pain which is refractory to treatment
with other medications and/or non-pharmacologic interventions and the low extent of opioid
use in  this  study may reflect the relatively low intensity and the less advanced nature of the
pain symptoms. Previously it has been stated that opioids are underutilized in older people due
to the negative attitudes towards this class of drugs; this might be the reason here for the low
prevalence of opioid use (Nwokeji et al., 2007, Sale et al., 2006). In addition, the role of opioids
in the management of nonmalignant chronic musculoskeletal pain may be an area of both
controversy  and  uncertainty  which  may  result  in  the  infrequent  use  of  opioids  (American
College of Rheumatology Pain Management Task Force, 2010). However, opioids are in steps 2
and 3 of the WHO analgesic ladder and they may be safer and more effective than NSAIDs in
those older people who have a high risk of suffering gastrointestinal, cardiovascular and renal
ADEs (American Geriatrics Society, 2009).
Despite the fact that the consumption of paracetamol and opioids increased substantially
between the years 1998–2005 in Finland (Finnish Medicines Agency and Social Insurance
Institution, 2013), this trend was not detected in the present study when compared to the study
of Hartikainen, Mäntyselkä et al. (2005). While the prevalence of NSAID use decreased, the
overall prevalence of paracetamol and opioid use remained static. This might be a cause of
concern, because it seems that there was no shift towards replacing NSAIDs with either
paracetamol or opioids although many participants stated that they were in pain in both
studies. The avoidance of ADRs or potential interactions should not be a reason to neglect the
treatment of pain. Although the growing trend in opioid consumption was not reflected in these
results, it maybe that the upswing of opioid use has occurred after the present study. However,
in Finland there has been undesirable feature of using transdermal fentanyl in preference to
morphine, oxycodone and hydromorphone for nonmalignant pain in community-dwelling
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older people (Bell et al., 2009). Several reasons may have influenced this trend, e.g. fentanyl may
be favoured due to its easier administration since it is mostly dispensed as a transdermal patch,
and there may also be commercial pressure, or fear of using morphine (Chinellato et al., 2003).
Choosing the appropriate pain treatment strategy involves assessing currently used
medications for existing illnesses and deciding on appropriate pharmacological pain
management  according to  the  type and severity  of  pain.  In  this  study,  the  assessment  of  pain
was based on self-report and thus it was not possible to distinguish the mechanisms behind the
painful  symptoms.  Thus,  it  is  not  possible  to  exclude  the  involvement  of  neuropathic  pain  in
those participants reporting pain especially because chronic pain is often caused by a mixture of
neuropathic and nociceptive components. For example, the participants reporting
musculoskeletal back or leg pain may have had a mixed pain involving the irritation of the
sciatic nerve, eventhough those participants did not report symptoms typical of neuropathic
pain during their interviews. It is possible, that those participants may have taken nonanalgesic
drugs (e.g. anticonvulsants or antidepressants) to alleviate their pain and this may have caused
some overestimation of the level of inadequate treatment of pain.
6.1.2 Pain-related mobility limitation
The finding that the risk of mobility limitations related to musculoskeletal pain was highest
among persons who used analgesics may also be a reflection of inadequate pain control. The
pattern of analgesic use may have influenced the result, since older people often use extremely
low doses of analgesics and the frequency of use is occasional rather than daily (Hartikainen et
al., 2005, Pahor et al., 1999, Sale et al., 2006). However, this is a potential mediator that has
rarely been examined and further studies will be needed to determine the role of analgesic use
in the risk of pain related mobility limitation. The fact that mobility limitations were most
common among those participants reporting musculoskeletal pain and using paracetamol when
compared to the other analgesic groups may reflect the poor efficacy of paracetamol to relieve
pain in some chronic diseases, such as severe osteoarthritis. It has been claimed that
paracetamol may be less effective than NSAIDs in the treatment of hip or knee pain resulting
from osteoarthritis (Towheed et al., 2006). Paracetamol is a suitable option as a step 1 drug for
mild pain,  but  in  view of  its  upper  dosing limit  and limited efficacy,  it  is  often insufficient  in
cases of moderate or severe pain, particularly when used alone. According to the WHO
analgesic ladder (1996) combination therapy or step 2 or step 3 analgesics should be considered
in those cases where paracetamol does not result in the desired response.
When analgesic users with musculoskeletal pain were examined then the mobility limitation
was associated with living alone, poor self-rated health, sedentary lifestyle and poor muscle
strength. Previous findings have indicated that a walking disability and poor self-rated health
are associated with a higher risk of death (Nuesch et al., 2011). These findings support the
proposal that it is important to combine pharmacological and nonpharmacological pain
treatment to promote the overall health of older individuals and improve their functional
abilities. The goal of the management of pain in older people should be at least to reduce it
down to a tolerable level so that the individual can maintain some mobility capabilities and
perform routine daily activities. In severe osteoarthritis-related pain there is often no effective
remedy except joint replacement, but this should be considered as a potential treatment option
if an older person’s mobility is threatened (Limnell, Jämsen et al. 2012). Older people often cope
with tolerable pain problems and even in these situations they may consider themselves being
as healthy as long as they have functioning cognition and they can remain as independent as
possible (Grime et al., 2010). It is important to treat pain effectively and at as early a stage as
possible to prevent functional and mobility restrictions that threaten autonomy, because once
the subject  enters  vicious  cycle  driven by chronic  musculoskeletal  pain,  it  is  difficult  to  break
out  of  the  downward spiral  of  muscle  weakness  and more and more functional  and mobility
limitations.
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A multidimensional individualized approach based on both pharmacological and
nonpharmacological strategies to manage pain might be the best way to improve pain control
and help to prevent mobility-related disability in older people. Physical exercise could
potentially confer benefits in pain management because it has been reported to enhance
functional mobility and relieve pain in older patients (Tse et al., 2011). In addition, sufficient
attention to comprehensive pain management could potentially increase the quality of life in
older people since pain and mobility problems often threaten physical and mental well-being
and lead to social isolation in daily life (Arola et al., 2010, Hawkins et al., 2013, Mackichan et al.,
2013). Since older people are at a high risk for pain and mobility decline (Gagliese and Melzack,
2013, Gill et al., 2012), it is important to develop new strategies for alleviating pain and
preventing mobility problems. In particular, randomized trials determining which approaches
to pain relief achieve the greatest advantages in relation to maintaining and promoting daily
functioning and mobility could help to optimize pain management in older people.
6.1.3 Persistent chronic pain
The prognosis of musculoskeletal chronic pain in community-dwelling older people seems
discouraging in the light of these present results. Chronic pain seems to be very persistent in its
nature since 74% of those community-dwelling older persons having chronic pain at baseline
also reported it during the two following years. This is a particularly alarming finding because
severe chronic pain is associated with increased mortality (Torrance et al., 2010). A high
persistence of chronic pain has been found also in the general population (ǃ25 years), since one
study revealed 79% persistence for chronic pain after an interval of 4 years (Elliott et al., 2002).
That study included only one follow-up point and the fluctuation between different pain
statuses was not identified. In contrast, another study has suggested that despite its high
prevalence, musculoskeletal pain in community-dwelling older adults (ǃ65 years) was mainly
intermittent (Thielke et al., 2012). However, that study included younger participants and the
pain was estimated by a single question (Have you had pain in your bones or joints in the last
year?) that did not reveal either the duration or the chronicity of pain. Furthermore, the
intensity of pain or the use of analgesics was not determined. In addition to the high persistence
of chronic pain noted here, 55–63% of individuals with persistent chronic pain rated their pain
as either moderate or severe. This differed from the results of Elliott, Smith et al. (2002) since the
prevalence of high intensity chronic pain grades was approximately 40% in their study. It is
evident that the different definitions of pain intensity may account for this apparent
discrepancy. Furthermore, the severity of chronic pain tended to be relatively static but in the
present study the percentage of high pain intensity decreased slightly during the follow-up
period. This may result from age differences in study populations, because older people tend to
take a more stoical attitude and they may be unwilling to complain even though they have pain
or they may claim to have a high pain tolerance (Helme and Gibson, 2001, Sale et al., 2006). In
addition, memory disorders may lead to an inability to describe the qualitative aspects of pain
and these are more common in older populations (Oosterman et al., 2014).
Despite the high persistence and intensity of pain, even those participants with chronic pain
were using analgesics on an as needed rather than a daily basis and more than 20% did not use
analgesics at all. This finding is in line with the earlier reports revealing that analgesic use on an
as  needed  basis  was  common  even  in  participants  suffering  daily  pain  severe  enough  to
interfere with their daily routines (Hartikainen et al., 2005). There seems to be a discrepancy
between the trend that older people do not use the maximum analgesic doses allowed or
prescribed, and the finding that older persons may choose not take analgesic drugs because
they feel that analgesic drugs are not effective enough to relieve their pain (Sale et al., 2006). The
tendendy of older people to minimise their perception of pain may result in poor adherence to
analgesic therapy. The patients may be reluctant to take analgesics, because drugs while viewed
as being important are often considered as a last resort for managing pain (Ross et al., 2001). In
addition, fear of adverse effects, addiction or drug interactions may lead to avoidance of
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analgesic use and reluctance to use analgesics often leads to activity restrictions and initiates the
spiral of mobility decline (Sale et al., 2006).
However, in the present study there was a trend that overall prevalence of analgesic use
increased among participants with persistent chronic pain whereas the pain intensity decreased.
Analgesia may not always achieve complete relief of relieve pain, but the goal should be on
reducing pain to the lowest level as possible and maintaining a good quality of life in spite of
the presence of pain (American Geriatrics Society, 2009). It is important to recognize that the
multiple  dimensions  of  persistent  chronic  pain cannot  be  explained simply by nociception i.e.
there may well be sociodemographic, clinical, genetic and affective factors as well as attitudes
which influence pain perception (Gagliese and Melzack, 2013, van Hecke et al., 2013). The use of
analgesics is not the only option to manage chronic pain e.g. the present study did not identify
if participants were utilizing nonpharmacological pain management strategies to alleviate their
pain. Even though the adoption of nonpharmacological methods is less frequent than the use of
analgesics, these methods may have provided significant benefits for some individuals (Barry et
al., 2005). Nonetheless, in the light of the present results it seems that persistent chronic pain
was  being  insufficiently  treated  because  a  significant  proportion  of  community-dwelling
participants were suffering from persistent chronic pain of high intensity.
Various pain assessment methods and treatment guidelines have been developed, but it
seems  that  they  are  not  being  systematically  used  in  clinical  practice.  This  may  be  a
consequence of  a  gap in  knowledge translation from research to  clinical  practice  or  it  may be
due  to  the  diminished  resources  and  current  hectic  nature  of  health  care  services.  Clinicians
should be more proactive to avoid situations where pain in older patients is being inadequately
recognized and treated. It has been reported that the most common way to determine pain is to
allow the patient to explain to the physician how they experience pain (Breivik et al., 2006).
However, this is not necessarily a practical method for use with an older patient, because older
age is associated with lower tendency to report pain and to express the need for pain treatment
and there is a significant risk that persistent pain will remain unrecognized or inadequately
treated (Cornally and McCarthy, 2011, Helme and Gibson, 2001). Comprehensive assessment of
pain may be a challenge in clinical practice because there is often a limited time to carry out all
the needed examinations and older people tend to have numerous health problems at the same
time. However, objective assessment methods should be used systematically and the results
should be documented sufficiently, because inadequate pain assessment and documentation
represents a risk that there will be poor pain management.
The management of chronic pain should be considered as a time-dependent dynamic
process, and therefore it is essential to create an individual plan for pain treatment and then to
evaluate pain and the effectiveness of treatment at regular intervals. If desired response is not
obtained or the patient suffers untolerable adverse effects related to analgesics, it is important to
try other options or move on to the next step according to the guidelines. The selection of the
appropriate analgesic should be based on a carefully assessment of individual benefits and
risks.  The regular  evaluation should include estimates  of  physical  activity  and how much the
pain interferences with the routines of daily life, because activity restrictions may be a marker
for inadequate pain treatment or patient’s poor adherence (Sale et al., 2006). By asking older
patients about activity restrictions, clinicians may be able to identify those individuals who are
not managing with their pain. In order to avoid nonadherence to pain treatment, it is important
to  discuss  with  their  older  patients  about  their  hopes,  fears  and  preconceptions  towards
analgesics and to explain the appropriate use of analgesics as aids to preventing activity
restrictions.
In addition, the preventive perspective should be taken into account more effectively in the
treatment of pain. It is well known that acute pain may become transformed into chronic pain,
although the mechanisms involved of the chronification process are incompletely understood.
Induction  of  central  sensitization  in  the  somatosensory  pathways  appears  to  be  a  common
pathophysiologic mechanism in the transition from acute to chronic pain (Pergolizzi et al.,
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2014). A central nervous system amplification occurs with increases in synaptic efficacy and
reductions in inhibition pathways such that the response to noxious stimuli becomes enhanced
in amplitude, duration and spatial extent. In addition, a low-threshold sensory input can
activate the pain sensation, because low-threshold mechanoreceptors converge with
nociceptors. Since older people are particularly vulnerable to suffering prolonged pain due to
impaired adaptation to painful stimuli and an inadequate regenerative capacity, efforts must be
undertaken to treat acute pain effectively to avoid its transition from acute to chronic pain
(Gagliese and Melzack, 2013).
6.1.4 Older persons' hopes concerning the management of chronic pain
The present study revealed that almost every other community-dwelling older person with
chronic musculoskeletal pain hoped that the physician would be paying more attention towards
his/her pain management. Not surprisingly, the percentage of those who would like to receive
more attention from the physician to their pain problems was highest among women and in the
youngest age group. A previous study with an outpatient setting found that older patients with
pain tended to receive a poorer quality of pain management than younger patients (Federman
et al., 2006). Physicians may underestimate their patients’ pain, especially in situations where
the patient is suffering chronic pain as well as when there is severe pain (Mäntyselkä et al.,
2001). This study did not investigate the treatment related expectations of those participants
who hoped for more attention towards their pain management. Some participants may have
had unrealistic expectations towards pain treatment, for example in those situations when the
pain cannot be eliminated but only alleviated. It is also possible that some persons feared or
even suffered from the adverse effects of analgesic drugs and they were not taking the drugs
according to instructions (Sale et al., 2006).
As previously mentioned, many older people have a tendency to take a pain diminishing
attitude. This may complicate the open communication with the physician making it difficult to
appreciate the severity of pain, or the patient’s hopes for pain treatment, particularly when
there  are  multiple  illnesses  requiring  therapy.  In  the  current  study  older  participants  were
actively asked about their pain and hopes concerning pain management, which may partly
explain why a significant proportion of them hoped that more attention would be paid to their
pain management. However, it was encouraging that the percentages of moderate to severe
pain as well as the hope for more attention to be paid to pain management decreased during the
study years in the participants with persistent chronic pain. In addition, the proportion of mild
pain and analgesic use increased simultaneously in the same participants. This is a trend
towards a modest step in the right direction in the management of pain in this challenging
group of older people with persistent chronic pain.
Unfortunately, it was not possible to determine the resons behind these hopes concerning
pain management and further research will be needed into this topic. In the light of the results,
it seems that the physicians need to take a more active role in the assessment of pain and to
discuss openly the hopes and concerns expressed by older people with respect to their pain and
its treatment (e.g. prognosis of pain, efficacy of treatment, and fear of addiction, adverse effects
or interactions). It has been reported that open-ended pain questions and the use of follow-up
questions will significantly increase the amount of important pain-related information provided
by older adults with osteoarthritis pain and thus adopting a narrative approach along with a
standardized pain assessment tool could prove useful (McDonald et al., 2009). However, older
patients should be given time to describe their pain before asking them further questions or
interrupting them in other ways, because it has been claimed that the interruptions might result
in loss of important information needed for appropriate pain management (McDonald and
Fedo, 2009). In addition, there is a report that educational seminars, in-service training and
handout materials may help to improve the safe and effective management of persistent pain
among older patients (Corrado-McKeon et al., 2013).
49
6.2 METHODOLOGICAL CONSIDERATIONS
This thesis was based on data from the population-based Geriatric Multidisciplinary Strategy
for the Good Care of the Elderly (GeMS) study conducted in 2004–2007. The extensive data
gathered for the GeMS study was appropriate for investigating the research questions
examined in this PhD study. This randomly selected population-based sample was large
enough (one sixth of those in the target population) to provide good representativeness of the
target population (Eaton 1998). Since age was the only inclusion criterion for participation in the
GeMS, the participants represented the full spectrum of the population aged 75 years or more.
The participation rate was 78.1% which can be considered as acceptable for a face-to-face health
survey (Greg 2002). Thus, the results are likely to be generalizable to older persons living in the
Kuopio area. However,  the  characteristics  of  older  population  and  prescribing  culture  may
differ between geographical regions and therefore the results of this present study may not be
generalizable to other countries or even to other parts of Finland.
The  attrition  of  participants  occurred  mainly  due  to  death  and  it  was  similar  in  the
intervention and control groups. Death is a rather natural form of attrition since the individuals
attending the GeMS study were old. Non-death attrition during the study period was relatively
uncommon (3% among community-dwelling study participants) and it did not differ
significantly between groups. In general, non-death attrition is potentially a greater source of
bias than death in longitudinal studies concerning older people (Brilleman et al. 2010). Thus, it
is unlikely that attrition conferred any significant bias in this study.
An important strength of the study was the data collection procedure that gathered diverse
information annually from the same population providing an opportunity to examine the
course  of  chronic  pain,  analgesic  use  and  related  issues  in  a  longitudinal  setting.  Data  on
prescription and OTC drug use was collected during interviews and the self-reported
information was verified from multiple sources (e.g. prescriptions, drug containers and medical
records) to minimize recall bias. It has been demonstrated that asking the respondents to name
the medicines they have been using is a reliable way to collect information about the prevalence
of drug use (Ademi et al., 2007). This data collection method meant that it was possible to
collect data on both prescription and OTC analgesic use which is an important strength of the
present study since many analgesic drugs are available for purchase without prescription or
reimbursement in Finland. It has been reported that OTC analgesics are frequently used
medications by individuals more than 75-years old (Kingsbury et al., 2013). However, the OTC
and prescription analgesics were not separated from each other in the data collection process
and thus it was not possible to analyse if there were differences in the patterns of OTC and
prescription analgesic use. This kind of data collection allowed taking nonadherence of
analgesic use into consideration and thus the data reflected actual analgesic use rather than the
dispensing or prescribing of analgesics. There have been some changes in the marketed
analgesics which occurred after the data collection, for example rofecoxib and tiaprofenic acid
are no longer marketed in Finland. However, the fact that it was not possible to investigate
whether non analgesic drugs (e.g. tricyclic antidepressants or anticonvulsants) were being used
for pain relief is a limitation of this study. An additional limitation is that the doses or
effectiveness of analgesic drugs used by the study participants were not evaluated.
The data collecting procedure included multiple previously used questions about presence,
sites, duration and intensity of pain enabling a good perspective of the pain. However, the fact
that the pain assessment was not based on a standardized pain questionnaire can be considered
as a limitation. In addition, due to a human error in the data collecting process at baseline in
2004, detailed pain information was not collected from participants in the control group.
Therefore the data for the year 2004 had to be excluded from the studies investigating chronic
musculoskeletal pain (III–IV). Participants were asked whether their symptoms resembled
“electric shocks, pressure-evoked pain, numbness, stabbing or tingling” suggestive of
neuropathic  pain,  but  it  was  not  possible  to  confirm the  clinically  important  characteristics  of
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pain types or causes. Therefore, possible occurrence of false classifications concerning pain
experiences should be noted. Furthermore, the successful treatment of chronic pain according to
the guideline definition achieves about a 30% improvement in pain symptoms (Abdulla et al.,
2013), but here it was not possible to determine minor changes in pain intensity, since moderate
and severe pain categories were pooled. However, even small decreases in the pain score, (eg. 8
to 6 when pain intensity would still be categorized as moderate to severe) may lower the pain to
a tolerable level and be significant at the individual level.
The internal validity of the study may have been influenced by several reasons. The fact that
the study population was relatively small in studies III and IV is a limitation and it may have
increased the probability of Type II errors (non-significant findings, when the null hypothesis is
actually false) due to a lack of power (Lane 2014). On the other hand, when analyzing large data
and several associations, there might be a risk for finding false positive results (type I error).
Despite the relatively small population size, the results provide an important overview of this
topic and a springboard for future studies. Unlike more specialized prescription drugs with
well-defined indications, analgesics are used universally for a broad and often nonspecific array
of  complaints.  Therefore  confounding by indication cannot  be  totally  excluded in  this  kind of
observational study, although morbidity was taken into account in the analyses.  Although the
pre-analyses confirmed the similarity of the characteristics between the intervention and the
control group, the fact that the intervention group was included in the fourth study may have
influenced the results. Participants in the intervention group may have developed differently
with regard to hope for more attention to pain management, even although pain was not on a
focus of the interventions.
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7 Conclusions
Based on the findings of the four studies included in this thesis, the following conclusions can
be drawn:
1. Almost  half  of  the  community-dwelling  older  participants  used  analgesics  and  the
majority of analgesic drugs were taken on an as needed rather than on a daily basis.
Women used more commonly analgesics than men, and paracetamol was the most
commonly used analgesic drug.
2. The risk of mobility limitation was highest among analgesic users experiencing pain. In
addition, the mobility limitation was associated with many factors including older age,
poor overall health, living alone, sedentary lifestyle and poor muscle strength.
3. Musculoskeletal chronic pain showed high persistence and intensity, since the majority
of those individuals with pain at baseline were still suffering from it also after two
follow-up years and the pain was rated mostly as moderate to severe. Persistent chronic
pain was significantly associated with poor health, mobility difficulties and joint
complaints.
4. The finding that almost half of community-dwelling older people with musculoskeletal
chronic pain hoped that the physician would be paying more attention to their pain
management emphasizes that there is a clear need for better strategies to manage pain in
this population. The persistent hope for more attention to pain management was related
to high pain intensity, daily analgesic use and poor health.
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8 Implications for the Future
8.1 CLINICAL IMPLICATIONS
1. A more comprehensive approach to pain assessment and management in older people.
The vicious circle where older people experiencing acute pain reduce their activity and
are threatened with disabling mobility limitations and the chronification of pain should
be interrupted by multidimensional pain management including nonpharmacological
and pharmacological strategies, and additional physical rehabilitation.
2. A more active role of clinicians to assess and manage pain.
Currently,  clinical  instruments  with  well  established  psychometric  properties  are
available for the purpose of assessing pain and how pain affects bodily function. Pain in
older patients and the effectiveness of their treatment need to be evaluated regularly.
Furthermore, the hopes and concerns of these patients regarding their pain and its
treatment should be discussed at length during the clinical consultation.
3. The availability of comprehensive pain assessment and management strategies.
Training of health care professionals in primary health care should include approaches to
promote the safe and effective management of pain. Better trained health professionals
may also be better at identifying those older patients needing to be referred to a specialist
before their pain has become persistent debilitating, even life-threatening.
8.2 SUGGESTIONS FOR FURTHER RESEARCH
1. A more detailed research is needed to explore whether the pattern of analgesic use (drug
type, frequency of use), is appropriate in relation to the pain (quality and intensity) and
its interference with daily routines in community-dwelling older people.
2. The effectiveness of pharmacological and nonpharmacological pain management
strategies should be investigated and the possible reasons behind unsuccessful pain
management should be determined.
3. The relationship between pain and pain management strategies with mobility limitations
should be observed in a longitudinal setting and with interventions intended to prevent
the persistence of pain and pain related mobility limitation; these approaches should be
developed and piloted in practice.
4. It is important to widen investigations to determine hopes and expectations of older
people with respect to pain assessment and management.
With more detailed information, better pain assessment and management strategies could
be developed and new guidelines provided to prevent and reduce pain and unnecessary
suffering among community-dwelling older people. In addition, more effective approaches
to the management of pain and the prevention of mobility limitations would be anticipated
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to prolong the time of independent living at home and thus to reduce the costs associated
with the institutional care.
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There are many confounding factors 
related to pain treatment in older 
people and concerns have been 
raised regarding the management of 
pain. This study aimed to determine 
the pattern of analgesic use, the 
persistence of chronic pain, and 
factors related to mobility limitation 
in community-dwelling older 
Finns. In addition, older persons’ 
perceptions of whether they hoped 
to receive more attention from 
the physician in the management 
of their pain were explored. It 
was shown that musculoskeletal 
chronic pain is often persistent in 
its nature and there is an evident 
need for better pain management in 
community-dwelling older people.
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